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SUMMARY 
ShcA is a bona fide adaptor protein without 
any enzymatic activity. Upon activation of 
receptor tyrosine kinases, ShcA associates 
with the receptor and becomes tyrosine 
phosphorylated. Phosphorylated ShcA recruits 
the Grb2/SOS complex to the membrane, 
where SOS stimulates the small GTPase Ras, 
resulting in the activation of the Ras/MAPK 
pathway. The fact that Grb2 binds directly to 
most of the receptor tyrosine kinases raises 
the question of how important is the role of Shc 
in mediating MAPK activation? Moreover, 
beside growth factor-induced MAPK activation, 
are there other pathways in which ShcA-
mediated MAPK activation is relevant? 
ShcA is expressed in three different 
isoforms: p46Shc, p52Shc, and p66Shc. These 
isoforms are all derived from a single gene and 
differ only in their N-terminal part. Although all 
isoforms are phosphorylated by receptor 
tyrosine kinases, and subsequently bind to 
Grb2, the p66Shc isoform does not seem to 
mediate MAPK activation. The individual 
contribution of p46Shc and p52Shc in mediating 
MAPK activation is also not clear. The fact that 
all isoforms are ubiquitously expressed, with 
some restrictions for p66Shc, complicates the 
experimental investigation of each isoform. 
Recently, p66Shc has been implicated in the 
regulation of apoptosis in response to oxidative 
stress.  
Using siRNA, we established a system which 
allows isoform-specific knockdown of ShcA 
proteins in tissue culture. Further development 
of this technique enabled us to express a 
single isoform in the absence of endogenous 
protein. This so-called “knockdown-in” 
technique is applicable for most proteins which 
are expressed in multiple isoforms, and allows 
the investigation of specific mutations against 
a clear background without overexpression. 
We used this technique to investigate the 
contribution of individual ShcA isoforms to 
EGF-induced MAPK activation in epithelial 
cells. Knockdown of all or single ShcA 
isoforms had no effect on EGF-induced Erk 
activation. Moreover, overexpression of p66Shc 
in non p66Shc-expressing MCF7 cells did not 
change EGF-induced proliferation or viability. 
These data suggest that EGF-induced MAPK 
activation in epithelial cells is ensured by a 
redundant coupling of Grb2 to the receptor.  
In a quest for growth factor-independent 
pathways involving Shc-mediated Erk 
activation, we investigated signaling 
downstream of the cell-cell adhesion molecule 
E-cadherin. We identified a previously 
unknown signaling pathway which is induced 
upon disruption of E-cadherin-dependent cell-
cell adhesion This pathway involves Src- and 
Shc-dependent Erk activation, which results 
subsequently in the expression of the 
urokinase plasminogen activator. Applying the 
knockdown-in technique revealed that p46Shc 
and p52Shc, but not p66Shc, were able to 
mediate MAPK activation upon disruption of 
cell-cell adhesion. This pathway directly links 
disruption of cell-cell adhesion with the 
expression of proteolytic enzymes, both 
processes involved in metastasis and wound 
healing. 
To learn more about the role of p66Shc in 
mediating oxidative stress-induced apoptosis 
in epithelial cells, the effect of p66Shc on cell 
viability was investigated. Although p66Shc has 
been shown to enhance stress-induced 
apoptosis in fibroblasts, endothelial cells, and 
T-cells, no effect on p66Shc expression was 
observed in two different epithelial cells, 
suggesting that the apoptotic response in 
epithelial cells is mediated in a p66Shc-
independent manner. 
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1.  INTRODUCTION 
 
This chapter provides insights into three 
different topics: (i) function of Shc proteins, (ii) 
E-cadherin-mediated cell-cell adhesion and (iii) 
RNA interference. 
 
1.1 The Shc adaptor proteins 
 
Shc proteins are prototype adaptor proteins 
which represent molecules that possess no 
apparent catalytic domains or activities. 
Adaptor proteins contain modular protein-
protein and protein-lipid interaction domains, 
such as src-homology domain 2 (SH2) and 3 
(SH3), phosphotyrosine binding domain (PTB), 
and pleckstrin homology (PH) domains, and 
are essential in propagating signals from a 
receptor in a coordinated fashion (Zhang et al., 
2002). 
The adaptor protein ShcA was initially 
identified as an SH2-containing proto-
oncogene involved in growth factor signaling. 
Since than, it has been shown to be an integral 
component implicated in the action of a wide 
variety of receptors, including receptor tyrosine 
kinases (RTKs), G protein-coupled receptors 
(GPCRs), immunoglobulin receptors, and 
integrins, as well as non-receptor tyrosine 
kinases such as Src and FAK. To date, three 
mammalian shc genes have been identified: 
shcA, shcB (sck), and shcC (N-shc/rai) 
(Nakamura et al., 1996; O'Bryan et al., 1996; 
Pelicci et al., 1996). All three shc genes 
encode proteins that are highly related in 
domain and structure. In the following section, I 
will provide an overview of the genomic 
organization and structural architecture of 
ShcA, hereafter referred to as Shc, along with 
its known functions in signal transduction. 
 
1.1.1. Genomic and structural 
organization of Shc  
 
1.1.1.1 Genomic organization and 
regulation of Shc expression  
 
The human shc locus maps to the 
chromosome 1q21 (Huebner et al., 1994). It 
contains 13 exons, which give rise to three 
different gene products: three isoforms of 
about 46, 52, and 66 kDa. All isoforms are 
generated either through RNA splicing or 
alternative translational initiation (Migliaccio et 
al., 1997; Pelicci et al., 1992) (Fig. 1.1.1.1). 
While the p46Shc/p52Shc transcript originates 
from the assembly of the non-coding exon 1 
with the 3' portion of exon 2 (exon 2a), and 
with exons 3−13, the p66Shc transcript is 
formed by the assembly of exons 2-13. A 
second mechanism that regulates transcription 
of the three Shc isoforms is the alternative 
usage of in-frame translational start codons. 
The transcript encoding p66Shc has three in-
frame ATGs that are responsible for the 
translation of p66Shc, and, to a lesser extent, 
p52Shc, and p46Shc. The p52Shc/p46Shc transcript 
contains two in-frame ATGs that are 
responsible for the translation of p52Shc and 
p46Shc (Migliaccio et al., 1997). The mouse shc 
locus is similarly organized and maps to 
chromosome 3 (Kojima et al., 2001; Migliaccio 
et al., 1997). 
Less is known about the molecular 
mechanisms that regulate the differential 
expression of the various Shc isoforms. It 
seems that different mechanisms control the 
expression of the two main Shc transcripts in 
different cell types. p46Shc/p52Shc are found 
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ubiquitously in every cell type, whereas p66Shc 
expression varies and is restricted to certain 
tissues and cell lines, being absent in brain, in 
most hematopoietic cell lines, in peripheral 
blood lymphocytes (PBL), and in a subset of 
breast cancer cell lines (Jackson et al., 2000; 
Pelicci et al., 1992; Stevenson and Frackelton, 
1998; Xie and Hung, 1996). Ventura et al. 
(Ventura et al., 2002) have recently identified 
epigenetic modifications, namely histone 
deacetylation and cytosine methylation, as 
mechanisms underlying transcriptional 
silencing of p66shc in specific cell types. 
Histone deacetylase inhibitors, or 
demethylating agents, were capable of 
restoring p66Shc expression in primary, 
immortalized, and transformed cells. 
Additionally, the p66shc-encoding locus could 
be reactivated in human PBL and mouse T-
cells by treatment with a variety of apoptogenic 
stimuli, such as H2O2, the calcium ionophore 
A23187, Fas ligation, and sequential 
engagement of CD4 and CD3 (Pacini et al., 
2004). In vivo, p66Shc expression has been 
found to be induced in circulating peripheral 
blood mononuclear cells of diabetic patients 
(Pagnin et al., 2005). 
Overall expression analysis has shown that 
Shc is expressed at its highest levels in the 
placenta, adipocytes, bronchial-epithelial cells, 
colorectal adenocarcinoma, cardiac myocytes, 
and smooth muscle cells of humans (human 
GNF SymAtlas). 
The family members ShcB and ShcC are 
derived from different genes, and their 
expression is restricted to the brain and 
neuronal tissue (Nakamura et al., 1996; 
O'Bryan et al., 1996; Ponti et al., 2005). Unlike 
shcA, only two isoforms are encoded by the 
shcB and shcC loci. 
 
 
Figure 1.1.1.1: 
Organization of human 
Shc locus and exon 
assembly of Shc 
transcripts. A schematic 
representation of the exon 
assembly in the 
p52shc/p46shc and p66shc 
encoding transcripts. Shc 
exons are indicated by 
boxes (black boxes are translated exons), the exon numbers are given above, and the splicing events 
are shown by the zig-zag line. The position of the three Shc ATGs is indicated below the exons (as 
described in (Migliaccio et al., 1997)). 
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1.1.1.2 Structural organization of Shc 
proteins 
  
Shc proteins are characterized by their 
specific modular organization, consisting of an 
amino-terminal phosphotyrosine-binding (PTB) 
domain, a central proline- and glycine-rich 
collagen homology domain (CH1), and a 
carboxy-terminal Src homology 2 (SH2) 
domain (Fig. 1.1.1.2). The unique feature 
thereby is the arrangement of the PTB and the 
SH2 domain in an N to C order (Luzi et al., 
2000). Shc proteins are evolutionarily well 
conserved and can be found in mammals, 
fishes, flies and worms. 
 
Figure 1.1.1.2: Domain structure of Shc 
proteins. All Shc isoforms share the same 
modular organization: N-terminal PTB domain, 
central collagen homology domain (CH1), and 
C-terminal SH2 domain. p66Shc contains an 
additional collagen homology domain (CH2). 
All known phosphorylation sites are indicated. 
 
A second phosphotyrosine-binding (PTB) 
domain, distinct from the SH2 domain, was 
discovered in Shc proteins (Blaikie et al., 1994; 
Kavanaugh and Williams, 1994). The unique 
feature of the Shc-PTB domain is that its 
binding to target sequences is determined by 
residues N-terminal to the phosphotyrosine, 
and is not influenced by residues C-terminal to 
the phosphotyrosine (Blaikie et al., 1997; Trub 
et al., 1995; Zhou et al., 1995a). Today, more 
than 160 proteins containing a PTB domain are 
known, including insulin receptor substrate 1/2 
(IRS-1/2), tensin, the epidermal growth factor 
receptor (EGFR) pathway substrate (Eps8), 
and the integrin cytoplasmic domain-
associated protein-1 (ICAP-1) (Schlessinger 
and Lemmon, 2003). 
The PTB domain shows remarkable 
structural similarity to pleckstrin homology (PH) 
domains, despite a very divergent primary 
sequence (Zhou et al., 1995c). In a similar way 
to PH domains, the Shc-PTB domain has been 
shown to bind acidic phospholipids such as 
PI(4,5)P2 and PI(4)P (Zhou et al., 1995c), and 
also PI(3,4,5)P3 (Rameh et al., 1997). The 
high affinity (KD=10-50 µM) of this binding 
suggests that the interaction of Shc with the 
membrane could occur independently of an 
interaction with tyrosine-phosphorylated 
receptors. Consistent with this idea was the 
identification of residues within the Shc-PTB 
domain that are critical for phospholipid binding 
and membrane localization and are distinct 
from the residues necessary for posphpo-
tyrosine binding (receptor binding). Over the 
last few years many different proteins, such as 
F-actin, SHIP (SH2-containing inositol 
polyphosphate 5 phosphatase), IRS-1 and 
PP2A (protein phosphatase type 2A), have 
been found to bind to the Shc-PTB domain in a 
phosphotyrosine-dependent or -independent 
manner (Kasus-Jacobi et al., 1997; Lamkin et 
al., 1997; Thomas et al., 1995; Ugi et al., 
2002).  
On the N-terminal edge of the PTB domain 
of p52Shc and p66Shc there is a serine 
phosphorylation site (Fig. 1.1.1.2) (El-Shemerly 
et al., 1997). Further studies have 
demonstrated that phosphorylation of this site 
is necessary for Shc binding to the 
phosphatase PTP-PEST and downregulation 
of insulin-induced Erk activation, most likely 
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through dephosphorylation of Shc (Faisal et 
al., 2002). 
The SH2 domain of Shc is located at the C-
terminus and was thought to be the only 
domain responsible for the recruitment of Shc 
to activated growth factor receptors before the 
identification of the Shc-PTB domain. It folds in 
a very similar manner to other SH2 domains 
(Mikol et al., 1995; Zhou et al., 1995b). Unlike 
the Shc-PTB domain, the target binding of the 
Shc-SH2 domain is determined by residues C-
terminal to the phosphotyrosine 
(Ravichandran, 2001). 
Between the PTB and the SH2 domain is the 
collagen homology (CH) 1 domain. This region 
is characterized by a large number of glycine 
and proline residues, but does not feature 
typical collagen-like repeats. While the PTB 
and the SH2 domains share high similarity, 
78% and 68% respectively, the CH1 domain is 
generally less well conserved between 
different species. However, within the 
mammalian Shc family members, three regions 
sharing a higher degree in homology are 
present in this domain. Two of these 
conserved regions comprise three critical 
tyrosine phosphorylation sites, Y239, Y240, 
and Y317, and additional amino acids 
surrounding the amino-terminal 
phosphorylation site suggesting an important 
role in the recognition of effector proteins 
(O'Bryan et al., 1996). Y317 is conserved in 
mammalian Shc proteins, but not seen in those 
of lower organisms. Y239 and Y240 are also 
present in Drosophila Shc (Lai et al., 1995), but 
Shc in C. elegans does not contain any of the 
tyrosine residues (Luzi et al., 2000). Both 
phosphorylation sites conform to the 
consensus Grb2-binding site and have been 
demonstrated to bind Grb2 (Velazquez et al., 
2000; Walk et al., 1998).  
The third conserved region maps as a 
binding site for adaptins which links the 
endocytic machinery of clathrin-coated pits 
with integral membrane proteins, suggesting a 
potential role of Shc in endocytosis. This 
region is only weakly conserved in Drosophila 
(Lai et al., 1995).  
p66Shc contains an additional N-terminal CH-
like domain (called CH2) (Migliaccio et al., 
1997), which is also found in the longer 
isoforms of ShcB and ShcC, but not in the 
Drosophila Shc protein (Luzi et al., 2000). In 
contrast to the CH1 domain, the CH2 domain 
can be serine/threonine phosphorylated in 
response to several stimuli such as oxidative 
stress (Migliaccio et al., 1999), 12-O-
tetradecanoylphorbol-13 acetate (TPA) (El-
Shemerly et al., 1997), and epidermal growth 
factor (EGF) (Okada et al., 1997). The 
phosphorylation of serine 36 (S36) has been 
linked to the role of p66Shc in oxidative stress 
response (Migliaccio et al., 1999) and will be 
discussed later. The physiological relevance of 
the threonine phosphorylation site (T29) has 
not yet been defined. 
 
1.1.2 Signaling and function of ShcA 
 
1.1.2.1 Role of Shc in mitogenic Ras/Erk 
signaling 
 
In vivo and in vitro studies from various 
laboratories have clearly established a role for 
Shc in Ras/MAPK activation (Lai and Pawson, 
2000; Pratt et al., 1999; Salcini et al., 1994). 
This is the only function of Shc of which the 
molecular mechanism is understood. Activation 
of RTKs results in the recruitment of Shc 
proteins and, subsequently, in Shc 
phosphorylation. Phosphorylated, hence 
activated, Shc binds to the Grb2/SOS complex. 
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The Shc/Grb2/SOS complex is then localized 
to the membrane through the interaction of Shc 
with the phosphorylated receptor via its PTB or 
SH2 domain (Blaikie et al., 1994; Pelicci et al., 
1992; Ravichandran et al., 1993). At the 
membrane in vicinity to Ras, SOS stimulates 
nucleotide exchange on Ras and, thereby, 
activation of Ras (Fig. 1.1.2.1) (Ravichandran, 
2001). GPCR, integrins, and cytokine 
receptors without intrinsic tyrosine kinase 
activity utilize other soluble and associated 
tyrosine kinases to phosphorylate Shc 
(Sayeski and Ali, 2003; Velazquez et al., 2000; 
Wary et al., 1996). In addition to translocating 
the Grb/SOS complex to the membrane, Shc 
seems to influence the extent of Ras 
activation. The Shc/Grb2 interaction increases 
the level of SOS bound to Grb2 in some 
systems, and SOS has been found 
preferentially in complexes that also contain 
Shc (Buday et al., 1995; Pronk et al., 1994; 
Ravichandran et al., 1995). Still, many 
receptors are able to directly recruit the 
Grb2/SOS complex, leading to Ras activation 
without the involvement of Shc (Arvidsson et 
al., 1994; Batzer et al., 1994; Schlaepfer et al., 
1998). In response to integrin ligation, 
however, Shc is necessary and sufficient for 
activation of the MAP kinase pathway (Wary et 
al., 1996). The ability of Shc to mediate Ras 
activation is largely dependent on the three 
tyrosine residues within its CH1 domain. 
Phosphorylation-deficient mutants exert 
dominant-negative activity, whereby the 
importance of distinct Shc tyrosines differs 
between the cell types and receptors 
(Ravichandran, 2001). 
 
 
Figure 1.1.2.1: Model for Shc-mediated Ras activation downstream of RTK. Shc binds to RTKs 
and recruits the Grb2/SOS complex which activates Ras. See text for details. 
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1.1.2.2 Role of Shc in c-myc activation and 
cell survival 
 
The observation that Shc is involved in c-
myc activation has led to two suggestions. 
First, Shc might play a role in signaling other 
than mediating Ras/MAPK activation and, 
second, the downstream signaling of 
Y239/Y240 and Y314 might have distinct 
properties (Fig. 1.1.2.2). In BaF cells, Gotoh et 
al. (Gotoh et al., 1996) showed that Shc could 
induce c-myc expression in response to IL-3 
stimulation which was dependent on 
Y239/Y240, but not on Y137. The same 
situation was demonstrated for EGF signaling 
in NIH3T3 cells (Gotoh et al., 1997). 
Subsequently, a role for Shc in c-myc gene 
activation has been shown in IL-2 signaling 
(Lord et al., 1998), in PDGF signaling (Blake et 
al., 2000), and in T-cell antigen receptor (TCR) 
signaling (Patrussi et al., 2005). However, it 
remains unclear how Shc mediates c-myc 
activation and what target genes are in turn 
affected by c-Myc. 
Induced c-myc expression downstream of IL-
2/3 and TCR correlated with survival signals in 
hematopoetic cells (Gotoh et al., 1996; Lord et 
al., 1998; Patrussi et al., 2005), suggesting an 
involvement of Shc in the regulation of a pro-
survival pathway via c-myc. Lord et. al. (Lord et 
al., 1998) observed Shc-dependent induction 
of proliferation and expression of c-myc, bcl-2 
and bcl-x in response to IL-2. Nevertheless, 
the proliferative response and the expression 
of bcl-family genes were not sufficient to 
mediate sustained cell survival and 
antiapoptotic effects associated with a 
complete IL-2 signal in murine T-cells. In a 
different study, a Shc chimera fused to the IL-2 
receptor β chain that lacks other cytoplasmic 
tyrosines was able to evoke PKB/AKT 
phosphorylation via the Shc/Grb2/Gab2/PI3K 
pathway, and might therefore be involved in 
the regulation of IL-2-mediated cell survival 
(Fig. 1.1.2.2) (Gu et al., 2000). 
The involvement of ShcB and ShcC in 
survival of neuronal cells has become more 
evident. Whereas ShcA is only expressed in 
proliferating neuroblasts and is downregulated 
in post-mitotic neurons, ShcB and ShcC 
remain expressed (Cattaneo and Pelicci, 1998; 
Conti et al., 1997). Mice with no ShcB and/or 
ShcC expression display a loss of certain types 
of peptidergic and nociceptive neurons (Sakai 
et al., 2000). It appears, therefore, that ShcA 
plays a role in neuronal proliferation, but ShcB 
and ShcC isoforms play a role in survival of 
post-mitotic neurons. 
Figure 1.1.2.2: Distinct signaling capacities 
of the major tyrosine phosphorylation sites. 
The three tyrosine phosphorylation sites and 
the signaling linked to these tyrosines are 
indicated. 
 
1.1.2.3 Role of Shc in cell adhesion, 
migration, and cytoskeletal organization 
 
The implication of Shc in processes such as 
cell adhesion, migration, and cytoskeletal 
organization originates from diverse reports in 
different contexts.  
Embryonic fibroblasts derived from Shc-
knockout mice have defects in spreading on 
fibronectin (Lai and Pawson, 2000). Similarly, 
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the regulation of cell adhesion and EGF-
induced migration on fibronectin required the 
interaction of Shc and α5β1 integrin in MCF7 
breast cancer cells (Mauro et al., 1999; Nolan 
et al., 1997). In addition, Shc has been shown 
to localize to focal adhesions and to interact 
with the focal adhesion kinase (FAK) (Barberis 
et al., 2000; Gu et al., 1999). Although Shc can 
be a substrate of FAK (Schlaepfer et al., 1998), 
their effects on cell migration seem to be 
distinct. While Shc stimulates random cell 
motility through activation of the Erk signaling 
pathway, FAK regulates directional persistent 
migration via p130Cas (Gu et al., 1999). In 
ErbB2-driven migration, Shc seems to be 
required for lamellipodia formation 
(reorganization of the actin cytoskeleton) and 
for mediating the interaction between the 
receptor and Memo, which is necessary for cell 
migration-required reorganization of the 
microtubule network (Marone et al., 2004). In 
support of this report, inhibition of EGF-
induced cell migration upon downregulation of 
Shc has also been observed in a different 
study (Nolan et al., 1997). In response to HGF, 
overexpression of Shc enabled enhanced 
migration and growth of melanoma cells 
(Pelicci et al., 1995a). Whether Shc stimulates 
proliferation or migration seems, at least 
partially, to be determined by external stimuli. 
In the presence of growth factors, Shc 
regulates DNA synthesis, but under growth 
factor-limiting conditions, Shc stimulates cell 
migration (Collins et al., 1999). To what extent 
both responses depend on Shc-induced MAPK 
activation, or activation of and cross talk with 
other signaling pathways, is not clear. 
However, in one case, a direct interaction 
between Shc and F-actin has been observed in 
PC12 cells in response to NGF (Thomas et al., 
1995). 
1.1.2.4 Role of Shc in tumorigenesis 
 
The ability of Shc to mediate mitogenic 
signaling raises the question of whether Shc 
can drive tumorigenesis. Although Shc proteins 
do not contain any enzymatic activity, 
overexpression of p46/52Shc was able to 
transform mouse fibroblasts and to enable 
them to form tumors in nude mice (Pelicci et 
al., 1992). In tumor cells with known tyrosine 
kinase gene alteration, Shc proteins were 
found to be constitutively phosphorylated and 
complexed with Grb2 and activated tyrosine 
kinases (EGFR, PDGFR, ErbB-2, Met, BCR-
Abl, and Ret) (Pelicci et al., 1995b). 
Underscoring the role of Shc in oncogenic RTK 
signaling, dominant negative Shc has been 
shown to block proliferation of ErbB-2 positive 
human breast cancer cell lines (Stevenson et 
al., 1999). 
More recently, an in vivo study has unveiled 
an unsuspected role for the Shc in RTK-
mediated vascular endothelial growth factor 
(VEGF) production and tumor angiogenesis 
(Saucier et al., 2004). Using RTK engineered 
to recruit a defined signaling protein, it was 
shown that the direct recruitment of either Grb2 
or Shc to an RTK oncoprotein is sufficient to 
induce transformation and metastasis (Saucier 
et al., 2002). The authors then extended this 
study in order to compare and define the role 
of Shc and Grb2 in RTK oncoprotein-driven 
tumorigenesis (Saucier et al., 2004). 
Fibroblasts expressing Shc-binding RTK 
oncoproteins induced tumors with short latency 
(approximately 7 days), whereas cells 
expressing Grb2-binding RTK oncoproteins 
induced tumors with delayed latency 
(approximately 24 days). The early onset of 
tumor formation resulted in the ability of Shc-
binding RTK oncoproteins to produce (VEGF) 
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in culture and an angiogenic response in vivo. 
Moreover, the use of fibroblasts derived from 
Shc-deficient mouse embryos demonstrated 
that Shc was essential for the induction of 
VEGF by the Met/hepatocyte growth factor 
RTK oncoprotein and by serum-derived growth 
factors.  
 
1.1.2.5 In vivo function of Shc 
 
1.1.2.5.1 Conventional Shc knockout 
 
The conventional knockout mouse created 
by Lai and Pawson (Lai and Pawson, 2000) 
clearly established a role for Shc in vivo. 
Ablation of exons 2 and 3, which encode the 
PTB domain, by gene targeting resulted in a 
loss of expression of all three Shc isoforms in 
homozygous mutants. The homozygous 
mutant embryos died at day 11.5 with severe 
defects in heart development and 
establishment of mature blood vessels. The 
cardiovascular system showed defects in 
angiogenesis and cell-cell contacts. Consistent 
with this, Shc was mainly expressed in the 
cardiovascular system of wild-type embryos. 
The Shc∆ex2/3 mutants also provided evidence 
for Shc in MAPK signaling in vivo. There was a 
loss of MAPK activation within the 
cardiovascular system of the Shc∆ex2/3 mutants, 
as revealed by whole mount immunostaining 
with phospho-specific Erk antibodies, when 
compared to wild-type embryos. Studies with 
Shc∆ex2/3 embryonic fibroblasts have 
demonstrated that Shc is necessary for MAPK 
signaling induced by a low concentration of 
growth factors, but at a high concentration of 
growth factors (50 ng/ml EGF or 25 ng/ml 
PDGF) no detectable difference in MAPK 
activation was observed. These data suggest 
that Shc sensitizes cells to low amounts of 
growth factors. Shc-deficient mouse embryonic 
fibroblasts (MEFs) also showed changes in 
focal contact organization and actin stress 
fibers when plated on fibronectin, underscoring 
the role of Shc in cytoskeletal organization. 
 
1.1.2.5.2 Conditional T-cell specific 
knockout and transgenic mice 
 
Efforts over the past 10 years have 
demonstrated that Shc plays a critical role in T-
cell receptor (TCR) signaling. The earliest 
evidence linking Shc to TCR-mediated 
signaling was the observation that Shc 
becomes tyrosine phosphorylated rapidly after 
TCR/CD3 crosslinking (Ravichandran et al., 
1993). Several studies followed showing that 
expression of dominant negative mutants of 
Shc inhibited TCR-mediated downstream 
signaling (Milia et al., 1996; Pacini et al., 1998; 
Pratt et al., 1999). To examine the relative 
significance of Shc compared to several other 
adaptors in T-cells, two genetic approaches 
were taken in mice (Zhang et al., 2002). The 
first approach involved the generation of a 
transgenic mouse with thymocyte-specific 
expression of a dominant negative form of Shc, 
where all tyrosine residues were mutated to 
phenylalanine (ShcFFF). The ShcFFF 
transgenic mice had a reduced thymus size, 
with significant reduction in thymocyte 
numbers. Further analysis revealed that T-
cellsShcFFF were blocked at the double negative 
stage (DN) of their development, which was 
characterized by the absence of CD4 and CD8 
markers (reviewed in (Zhang et al., 2003)). The 
authors did not observe any increase in the 
apoptotic fraction of the DN cells in ShcFFF 
transgenic mice compared to wild-type mice. 
More recent studies using pulse BrdU injection 
have demonstrated a defect in proliferation of 
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the late DN stage cells mediated by the pre-
TCR (Fig. 1.1.2.5.2). The same phenotype was 
also obtained using the second approach, 
conditional Shc knockout mice, with a nearly 
complete loss of Shc protein expression in 
thymocytes. Thus, both Shc expression and its 
tyrosine phosphorylation play an essential and 
non-redundant role in thymic T-cell 
development and proliferation. 
 
Figure 1.1.2.5.2: Role of Shc in T-cell 
development. Inducible expression of ShcFFF 
as a transgene or inducible loss of Shc protein 
expression arrests thymic development at the 
double negative (DN) stage. The block is seen 
where signaling from the pre-TCR occurs. The 
role of Shc during selection at the double 
positive (DP) stage has not yet been 
determined. SP: single positive; CD4 and CD8 
are T-cell markers (adapted from (Zhang et al., 
2003)). 
 
1.1.2.6 Role of p66Shc  
 
The cDNA encoding the largest isoform, 
p66shc, was cloned in 1997, 5 years after the 
discovery of the two smaller isoforms 
(Migliaccio et al., 1997). As already mentioned, 
it encompasses an additional CH2 domain on 
its N-terminus containing a serine (S36) and 
threonine (T29) phosphorylation site. Unlike 
p46/52Shc, overexpression of p66Shc does not 
transform mouse fibroblasts (Migliaccio et al., 
1997), suggesting a function distinct from the 
other two isoforms. Indeed, p66Shc does not 
increase EGF-induced MAPK activation, 
although it is tyrosine-phosphorylated upon 
EGF stimulation, binds to activated EGFRs, 
and forms stable complexes with Grb2 
(Migliaccio et al., 1997) (Fig. 1.1.2.6-1A). 
Furthermore, it has been shown that p66Shc 
expression inhibits EGF-induced c-fos 
promoter activation (Fig. 1.1.2.6-1A). The 
molecular mechanism is not understood, taken 
into account that p66Shc expression did not 
inhibit Erk activation. However, the inhibition 
was attributed to the CH2 domain, since it 
retained the inhibitory effect of p66Shc on the c-
fos promoter (Migliaccio et al., 1997). In 
contrast, an independent study has shown that 
p66Shc can function in a dominant-interfering 
manner and inhibits Erk activation downstream 
of EGFR signaling (Fig. 1.1.2.6-1B) (Okada et 
al., 1997). These authors demonstrated not 
only tyrosine but also serine/threonine 
phosphorylation of p66Shc in response to EGF, 
which impairs its ability to associate with the 
tyrosine-phosphorylated EGFR, but not with 
Grb2. Co-immunoprecipitation of Shc and Grb2 
from cells overexpressing the p45/52Shc 
isoforms, versus p66Shc, directly demonstrated 
a competition of binding for a limited pool of 
Grb2 proteins (Fig. 1.1.2.6-1B). Inhibition of the 
Ras/MAPK pathway by p66Shc in an S36 
phosphorylation-dependent manner has also 
been found following TCR downstream 
signaling (Pacini et al., 2004). Furthermore, 
p66Shc-deficient T-cells have been reported to 
proliferate faster than their normal counterparts 
in response to limiting ligand concentration, 
supporting an antagonistic activity of p66Shc on 
mitogenic signaling (Pacini et al., 2004). The  
 
  INTRODUCTION 
 15 
 
 
 
Figure 1.1.2.6-1: Possible mechanism of 
p66Shc function in Ras/MAPK signaling. See 
text for details (A) p66Shc binds Grb2 in a 
conformation which does not allow activation of 
Ras. (B) p66Shc competes with p46/52Shc for 
Grb2 binding. (C) p66Shc binds to RasGAP and 
negatively influences Ras activation. 
 
 
mechanism whereby p66Shc-bound Grb2 
becomes uncoupled from Ras remains to be 
determined. It is possible that p66Shc binds 
Grb2 or the Grb2/SOS complex in a 
conformation which does not allow SOS to act 
as a guanine exchange factor for Ras (Fig. 
1.1.2.6-1A). However, the finding that p66Shc 
participates in a complex which also includes 
RasGAP during early morphogenetic events in 
Xenopus gastrulation (Dupont and Blancq, 
1999) suggests a different mechanism for the 
negative control of Ras/MAPK activation by 
this protein (Fig. 1.1.2.6-1C). Whatever the 
mechanism is, p66Shc does not mediate growth 
factor-induced MAPK activation, and its 
expression might provide a mechanism for 
fine-tuning the Ras/MAPK pathway. 
More recently, loss-of-function studies have 
unveiled an unexpected role of p66Shc in 
ageing and in the apoptotic response to 
oxidative stress (Migliaccio et al., 1999). 
p66Shc-deficient mice exhibit a lifespan about 
30% longer than wild-type. Moreover, they 
survive longer after treatment with paraquat, a 
drug that increases the production of reactive 
oxygen species (ROS) and, therefore, 
oxidative stress. Increased resistance to 
oxidative stress or oxidative stress-inducing 
agents such as UV and H2O2 can be correlated 
with a reduction in the apoptotic responses to 
these stimuli in p66Shc-/- fibroblasts. A 
protective effect of p66Shc ablation against 
apoptosis in thymocyte and peripheral T-
lymphocyte has also been reported recently 
(Pacini et al., 2004). Conversely, p66Shc 
overexpression results in enhanced stress-
induced apoptosis in fibroblasts, endothelial 
cells and T-cells (Pacini et al., 2004; Trinei et 
al., 2002). The proapoptotic activity of p66Shc is 
strictly dependent on phosphorylation of S36  
in the CH2 domain. S36 phosphorylation is 
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observed in response to many stimuli, 
including H2O2, UV (Migliaccio et al., 1999), 
Fas ligation (Pacini et al., 2004), and taxol 
(Yang and Horwitz, 2002), but also in response 
to EGF (Okada et al., 1997) and insulin (Kao et 
al., 1997). Depending on the cellular context 
and on the identity of the stimulus, either Erk, 
JNK, or p38 MAPK is responsible for S36 
phosphorylation (Le et al., 2001; Okada et al., 
1997; Yang and Horwitz, 2002). Taken 
together, these results suggest that p66Shc acts 
as a sensor of intracellular concentration of 
ROS (Fig. 1.1.2.6-2). 
Further experiments aimed at understanding 
the mechanisms underlying the role of p66Shc 
in regulating oxidative stress-induced 
apoptosis have revealed that p66Shc is a 
downstream effector of the tumor suppressor 
p53 (Trinei et al., 2002). It is required for p53-
induced release of cytochrome C from 
mitochondria, and subsequent caspase 3 
activation (Fig. 1.1.2.6-2). Again, the capacity 
of p66Shc to mediate p53-dependent apoptosis 
requires phosphorylation of S36. The release 
of cytochrome C in oxidative stress is the 
endpoint of the p53-dependent transcriptional 
activation of redox related genes. The resulting 
rise of ROS levels affects the mitochondrial 
membrane potential, leading to membrane 
permeability transition and cytochrome C 
release (Li et al., 1999; Polyak et al., 1997). 
Cyclosporin A, an inhibitor of the mitochondrial 
permeability transition pore which blocks 
oxidative stress-induced apoptosis of wild-type 
MEFs, is able to prevent re-expressed p66Shc 
from restoring apoptotic responses to oxidants 
in p66Shc-/- MEFs, suggesting that p66Shc may 
regulate mitochondrial permeability transition, 
and 
 
 
 
Figure 1.1.2.6-2: p66Shc senses ROS and mediates oxidative stress-induced apoptosis. ROS 
activate one of the MAPKs, which in turn phosphorylates p66Shc on S36. S36 phosphorylation is 
necessary for cytochrome C release and subsequent apoptosis. p53 acts upstream of p66Shc and 
enhances p66Shc protein stability, leading to p66Shc accumulation. p53-induced apoptosis is dependent 
on p66Shc expression. 
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hence cytochrome C release, by modulating 
the production of ROS (Orsini et al., 2004). 
Indeed, intracellular ROS levels are drastically 
reduced in p66Shc-/- cells and enhanced in 
p66Shc overexpressing cells (Nemoto and 
Finkel, 2002; Orsini et al., 2004). Furthermore, 
p66Shc has been found to localize to 
mitochondria and to be associated with Hsp70. 
(Orsini et al., 2004). The best evidence was 
derived from a recent report by Giorgio et al. 
(Giorgio et al., 2005), which clearly established 
a role for p66Shc in the generation of ROS. 
p66Shc was found to function as a redox 
enzyme that generates mitochondrial ROS as 
signaling molecules for apoptosis (Fig. 1.1.2.6-
3). It does so by utilizing reducing equivalents 
of the mitochondrial electron transfer chain 
through the oxidation of cytochrome C. 
Interestingly, S36 phosphorylation was not 
observed in the mitochondrial pool of p66Shc: 
instead a different region was necessary for 
the redox activity of p66Shc. It seems, therefore, 
that p66Shc exists in two different pools, a 
cytoplasmic one and a mitochondrial one. 
Significant translocation of p66Shc from cytosol 
to mitochondria does not occur following 
apoptotic signals, suggesting that S36 
phosphorylation might serve other, 
nonmitochondrial, activities of p66Shc which are 
also needed to exert its proapoptotic function.  
A second mechanism by which p66Shc could 
influence ROS levels was suggested by 
Nemoto et al. (Nemoto and Finkel, 2002) (Fig. 
1.1.2.6-4). They linked p66Shc expression to the 
transcriptional activity of the forkhead family 
transcription factor, FKHRL1. In quiescent 
cells, FKHRL1 localizes predominantly in the 
nucleus where it positively regulates 
transcription of genes such as catalase, 
implicated in ROS scavenging. Oxidative 
stress most probably promotes FKHRL 
phosphorylation in a PKB-dependent manner, 
and subsequent exclusion from the nucleus 
results in a reduction of its transcriptional 
activity. Phosphorylation and cytoplasmic 
localization of FKHRL in response to H2O2 was 
abrogated in p66Shc-deficient MEFs. 
Accordingly, FKHRL-dependent transcription of 
the catalase gene was augmented in these 
cells, suggesting a pivotal role of p66Shc in the
 
Figure 1.1.2.6-3: Model of p66Shc redox 
activity during mitochondrial 
apoptosis. Proapoptotic signals induce 
release of p66Shc from a putative 
inhibitory complex. Active p66Shc then 
oxidizes reduced cytochrome C (red) and 
catalyzes the reduction of O2 to H2O2. 
Permeability transition pore opening by 
H2O2 then leads to swelling and 
apoptosis. NADH-Cyt B5 reductase is 
indicated as an additional putative source of reduced cytochrome C (taken from (Giorgio et al., 2005)). 
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redox-dependent inactivation of FKHRL1 and, 
thereby, in the control of ROS. 
 
Figure 1.1.2.6-4: p66Shc regulates FKHRL1 
transcriptional activity. p66Shc expression 
enhances PKB phosphorylation via an 
unknown mechanism. This leads to a decrease 
in FKHRL1 transcriptional activity due to 
phosphorylation by PKB which causes its 
retention in the cytoplasm. Finally, ROS-
detoxifying enzymes such as catalase are less 
expressed. 
 
The ability to generate ROS and to regulate 
expression of scavenger proteins makes 
p66Shc an attractive target for therapies against 
vascular diseases, which are strongly 
mediated by ROS. Indeed, deletion of p66Shc 
reduces systemic and tissue oxidative stress, 
vascular cell apoptosis and early 
atherogenesis in mice fed a high-fat diet 
(Napoli et al., 2003). p66Shc-deficient mice 
were also resistant to the 
proapoptotic/hypertrophic action of Angiotensin 
II (Ang II). Consistently, in vitro experiments 
have shown that Ang II causes a higher rate of 
apoptotic death in cardiomyocytes isolated 
from p66Shc(+/+) hearts than in those isolated 
from p66Shc(-/-) hearts (Graiani et al., 2005). In 
perspective, inhibition of p66Shc may be 
envisioned as a novel way to prevent the 
deleterious effects of ROS-mediated diseases 
in general and of Ang II on the heart in 
particular. 
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1.2 Signaling of the E-
cadherin cell-cell adhesion 
protein 
 
The cadherins constitute a major class of 
adhesion molecules that support calcium-
dependent, homophilic cell-cell adhesion in all 
solid tissues of the body. They mediate cell-cell 
recognition events, bring about morphological 
transitions that underlie tissue formation, and 
maintain tissue architecture in the adult 
organism. The next paragraph will give a brief 
introduction of E-cadherin-dependent cell-cell 
adhesion with major emphasis on its tumor 
suppressing function and its signaling 
capacities. 
 
1.2.1 E-cadherin-dependent cell-cell 
adhesion 
 
1.2.1.1 E-cadherin: a member of the 
classical cadherins 
 
Cadherins represent a large superfamily 
which includes classical cadherins, 
desmosomal cadherins, atypical cadherins, 
proto-cadherins and cadherin-related signaling 
molecules (Gumbiner, 2005). E-cadherin is a 
prototype family member and belongs to the 
classical cadherins. Classical cadherins were 
originally named for the tissue in which they 
are most prominently expressed. Later, it 
became clear that most cadherins can be 
expressed in many different tissues. E-
cadherin (epithelial cadherin) is expressed 
primarily in epithelial cells and is associated 
with the zonula adherens (which is also known 
as adherens junctions) of the epithelial 
junctional complex (Fig. 1.2.1.1-1). Adherens 
junctions represents a specialized form of 
cadherin-based adhesive contacts which helps 
cells to form a tight, polarized cell layer that 
can perform barrier and transport functions 
(Gumbiner, 2005).  
Figure 1.2.1.1-1: Epithelial junctional 
complex. Adhesion between vertebrate cells is 
generally mediated by three types of adhesion 
junction: adherens junction (zonula adherens), 
tight junction (zonula occludens), and 
desmosomes. Electron micrograph of an 
epithelial junctional complex containing zonula 
adherens (ZA), zonula occludens (O), and 
desmosome (D). The ZA junction completely 
encircles the apex of the epithelial cell, but only 
a section through the junction is shown. The 
membranes of the two cells align tightly at the 
junction, with an extracellular gap of 250Å. The 
cytoplasmic surface of the junction appears as 
a dense plaque, presumably made up of 
cytoskeletal proteins, which associates with 
actin filament (taken from (Gumbiner, 2005)). 
 
Classical cadherins are single-pass 
transmembrane proteins. They contain five 
cadherin domains on their extracellular part 
which confer specific adhesive binding, and 
homophilic protein-protein interactions  
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Figure 1.2.1.1-2: The classical cadherin-
catenin complex. Cadherin is a parallel, or 
cis, homodimer. The extracellular region of 
classical cadherins consists of five cadherin-
type repeats (extracellular cadherin domains) 
that are bound together by Ca2+ ions (yellow 
circles) to form stiff, rod-like proteins. The core 
universal-catenin complex consists of p120-
catenin, bound to the juxtamembrane region, 
and β-catenin, bound to the distal region, 
which in turn binds α-catenin. In a less well 
understood way, α-catenin binds to actin and 
actin-binding proteins, such as vinculin, α-
actinin, or formin-1 (taken from (Gumbiner, 
2005)). 
 
between two cadherin molecules on two cells. 
The exact structure of the homophilic bond is 
still a matter of debate (Gumbiner, 2005), but 
an intriguing possibility is that some of the 
existing models represent different 
conformational states that are important for the 
regulation of adhesion. The presence of a 
conserved cytoplasmic tail that associates with 
cytoplasmic proteins, the catenins, is a second 
characteristic which distinguishes classical 
cadherins from other members of the cadherin 
superfamily (Fig. 1.2.1.1-2) (Takeichi, 1995). 
α-catenin interacts, through β-catenin, with the 
distal part of the cadherin cytoplasmic domain. 
γ-catenin (also known as plakoglobin) can bind 
to the same site as β-catenin in a mutually 
exclusive way, whereas another catenin, p120-
catenin, interacts with a more proximal region 
of the cytoplasmic domain.  
 
1.2.1.2 Function of catenins in the E-
cadherin adhesion complex 
 
The main function of catenins is the 
conversion of the specific homophilic binding 
capacity of the E-cadherin extracellular domain 
into a stable cell-cell adhesion. Although the E-
cadherin extracellular domain alone possesses 
homophilic binding properties, stable cell 
adhesion requires the cadherin cytoplasmatic 
tail and associated proteins (Yap et al., 1997). 
α-catenin can mediate physical links 
between cadherin and the actin cytoskeleton, 
either by directly binding actin filaments or 
indirectly through other actin-binding proteins 
such as vinculin and α-actinin (Fig. 1.2.1.2A). 
Besides linking cadherins to the actin 
cytoskeleton, catenins are believed to play 
additional roles. β-catenin is a well known 
signaling molecule in the Wnt pathway (see 
below), and catenins can interact with other 
signaling molecules, such as GTPases 
(Goodwin et al., 2003), PI3K (Woodfield et al., 
2001), and formin-1 (known to nucleate actin 
polymerisation) (Kobielak et al., 2004), to 
influence the state of the actin cytoskeleton 
(see below) (Fig. 1.2.1.2B).  
The core function of p120-catenin is to 
regulate cadherin turnover (Reynolds and 
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Roczniak-Ferguson, 2004). Loss of p120-
catenin leads to significantly reduced levels of 
E-cadherin in epithelial cells (Davis et al., 
2003). Thus, p120-catenin directly influences 
adhesive strength by controlling the amount of 
E-cadherin available at the cell surface for 
adhesion.  
Furthermore, the adhesive strength of 
cadherins is changed by posttranslational 
modifications of p120-catenin and β-catenin. 
Although poorly understood, tyrosine 
phosphorylation of catenins is believed to 
regulate the conformation or organization of 
cadherins. It is thought that phosphorylation of 
catenins could lead to a disruption of 
dimerization and reduced clustering of the 
cadherin molecules at the surface, resulting in 
an inactive, or less adhesive, conformation 
(Fig. 1.2.1.2C).  
 
1.2.1.3 Function of the E-cadherin-catenin 
complex 
The E-cadherin-catenin complex is essential 
for the formation of epithelia in the embryo, 
and maintenance of epithelial structure in the 
adult. It carries out different functions, including 
cell-cell adhesion, cytoskeletal anchoring, and 
signaling. The expression of different types of 
cadherins mediates selective cell recognition 
events that are responsible for the sorting of 
different groups of cells in developing tissues, 
and the formation of selective connections 
between neurons in the developing nervous 
 
 
Figure 1.2.1.2: Function of catenin proteins in the E-cadherin-catenin complex. There are three 
ways in which catenins contribute to the cadherin function. (A) α-catenin provides a direct physical link 
to the actin cytoskeleton through interaction with E-cadherin-bound β-catenin and actin or actin-
binding proteins such as vinculin and α-actinin. (B) Catenins bind to or influence signaling molecules 
(GTPases, formin-1, PI3K) known to control the actin cytoskeleton. (C) Phosphorylation of catenins 
might control the adhesive strength of the cadherin-catenin complex. Depicted is a hypothetical 
example where phosphorylation of catenins could lead to a disruption of dimerization and reduced 
clustering of cadherin molecules at the cell surface, resulting in an inactive or less adhesive 
conformation. Ca2+ ions are indicated by yellow circles. EC: extracllular cadherin domain (taken from 
(Gumbiner, 2005)). 
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system (Gumbiner, 2005). In cell culture, a 
mixed population of cells expressing different 
cadherins become sorted by adhering only to 
those cells expressing the same cadherin (Yap 
et al., 1997). During development, segregation 
of cells into distinct tissues is accompanied by 
changes in the complement of cadherins 
expressed by the cells. The specificity of 
homophilic binding is therefore a fundamental 
mechanism by which cadherins influence the 
organization of various cell types into tissue 
(Yap et al., 1997). However, different 
cadherins can be promiscuous with regards to 
their adhesive binding properties, with 
evidence for heterophilic adhesion between 
different classical cadherins. The level of 
cadherin expression, and presumably therefore 
the overall strength of adhesion, has also been 
found to strongly influence cell-sorting 
behavior, independently of the type of cadherin 
expressed (Gumbiner, 2005). 
The importance of E-cadherin-mediated cell 
adhesion is also highlighted by the fact that its 
disturbance is causally involved in cancer 
development. 
 
1.2.2 E-cadherin as a tumor 
suppressor 
 
The majority of human cancers (ca. 80-90%) 
originate from epithelial cells. In most, if not all, 
of these epithelial-derived cancers, E-cadherin-
mediated cell-cell adhesion is lost, concomitant 
with the transition from benign, non-invasive 
tumor to malignant, invasive tumor. Although 
E-cadherin expression is maintained in most 
differentiated tumors, including carcinomas of 
the skin, head and neck, breast, lung, liver, 
colon, and prostate, there seems to be an 
inverse correlation between E-cadherin levels 
and cancer grade (Birchmeier and Behrens, 
1994; Hirohashi, 1998). This observation has 
prompted an examination of the functional role 
of E-cadherin in tumor progression. Behrens et 
al. (Behrens et al., 1989) showed that epithelial 
cells acquire invasive properties when 
intercellular adhesion is specifically inhibited by 
the addition of E-cadherin function-blocking 
antibodies; the separated cells then invade 
collagen gels and embryonic heart tissue. 
Subsequently, several groups have 
demonstrated that re-establishing the 
functional cadherin complex by forced 
expression of E-cadherin results in a reversion 
of an invasive, mesenchymal phenotype to a 
benign, epithelial phenotype of cultured tumor 
cells (Birchmeier and Behrens, 1994; Navarro 
et al., 1991; Vleminckx et al., 1991). Based on 
these data, it has been proposed that the loss 
of E-cadherin-mediated cell-cell adhesion is a 
prerequisite for tumor cell invasion and 
metastasis formation. The in vivo proof that 
loss of E-cadherin is not a consequence of de-
differentiation, but rather the cause of tumor 
progression, was made by Christofori and 
colleagues (Perl et al., 1998). Intercrossing 
RipTag2 mice, which provide a model of 
pancreatic carcinogenesis, with transgenic 
mice that maintain E-cadherin expression in β-
cell-derived tumor cells resulted in the arrest of 
tumor development at the adenoma stage, 
whereas expression of a dominant-negative 
form of E-cadherin induced early invasion and 
metastasis. Very recently, a second study has 
demonstrated causal evidence for the 
involvement of E-cadherin in tumor 
progression. A group from the Netherlands 
introduced a conditional loss-of-function 
mutation in the E-cadherin gene into mice that 
carry p53 mutations. Although tissue-specific 
inactivation of E-cadherin alone did not result 
in tumor formation, the combined inactivation 
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of E-cadherin and p53 led to the accelerated 
development of mammary gland and skin 
tumors. Moreover, loss of E-cadherin induced 
a phenotypic change from non-invasive to 
highly invasive mammary gland tumors, and a 
conversion from ductal to lobular carcinomas 
(Birchmeier, 2005). These results show that 
the loss of E-cadherin-mediated cell-cell 
invasion is one rate-limiting step in the 
progression from adenoma to carcinoma and 
subsequent formation of tumor metastases.  
Downregulation of E-cadherin is often part of 
a process called epithelial-to-mesenchymal 
transition (EMT), which is characterized by the 
loss-of-expression of epithelial genes and the 
gain-of-expression of mesenchymal genes 
(Thiery, 2002). EMT is a crucial event during 
tumor metastasis but also occurs in normal 
embryonic development, for example during 
gastrulation (Fig. 1.2.2). Activation of RTK 
[fibroblast growth factor receptor (FGFR), 
EGFR family, transforming growth factor-β 
(TGF-β) receptor, insulin-like growth factor 
receptor (IGFR), hepatocyte growth factor 
receptor (HGFR)] signaling is able to induce 
EMT via stimulation of PI3K, Src, Ras and 
Rac. Signaling downstream of EGFR, c-Met 
and FGFR, as well as Src, results in tyrosine 
phosphorylation of E-cadherin, β-catenin and 
p120-catenin, leading to a disassembly of the 
cadherin-catenin complex, disruption of 
cadherin-mediated adhesion and cell 
scattering. Tyrosine phosphorylation-mediated 
ubiquitination and subsequent proteasomal 
degradation of E-cadherin or increased 
endocytosis of E-cadherin seem to be 
mechanisms underlying this observed 
disassembly (Fujita et al., 2002; Kamei et al., 
1999). Moreover, induction of expression of 
transcription factors, such as Snail and Slug, 
has been observed downstream of RTK 
signaling (Thiery, 2002). Snail, Slug, SIP1, and 
E12/47, as well as Twist, are factors which 
repress transcription from the E-cadherin 
promoter via the E-boxes (Cavallaro and 
Christofori, 2004; Yang et al., 2004).  
β-catenin is also actively involved in EMT 
(Fig. 1.2.2) and its role as a signaling molecule 
will be discussed later. 
In addition to EMT, which is a rather 
organized process leading to downregulation 
of E-cadherin expression, various other 
mechanisms are involved in the disruption of 
cell-cell adhesion during tumor progression. A 
variety of genetic mechanisms, such as 
deletion or mutational inactivation of the gene, 
or gene mutations which result in the 
expression of a non-functional protein, cause 
loss of E-cadherin expression or function, 
especially in diffuse gastric cancer (Birchmeier 
and Behrens, 1994; Bracke et al., 1996; 
Strathdee, 2002). Silencing of the E-cadherin 
gene by hypermethylation of promoter regions 
occurs frequently in carcinoma cell lines, in 
thyroid carcinomas, and in several other 
cancer types (Di Croce and Pelicci, 2003; 
Hirohashi, 1998). More recently, proteolytic 
degradation of E-cadherin by matrix-metallo 
proteases (MMPs) has been described as a 
mechanism by which cell-cell adhesion can be 
disrupted. Cleavage of E-cadherin results in 
not only the disruption of cell-cell adhesion, but 
also the production of a soluble 80-kDa E-
cadherin fragment that itself disrupts cell-cell 
adhesion in a dominant-interfering manner, 
thereby promoting tumor progression (Noe et 
al., 2001; Wheelock et al., 1987).  
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Figure 1.2.2: Epithelial-mesenchymal transition (EMT). Epithelial cells lose the expression of 
epithelial-specific genes, such as E-cadherin, and acquire the expression of mesenchymal genes 
(vimentin, collagens, integrins). EMT causes cells to lose apical-basal polarity (shown on the left) and 
gain a fibroblast-like morphology, high motility and invasive properties (shown on the right). (A) 
Transcription factors (such as Snail and Slug) have been identified that control the expression of E-
cadherin by binding directly to E-boxes in the gene promoter. Other factors, such as growth factors 
and their receptors, the tyrosine kinase src, and cytoplasmic G-proteins (such as rac) can also 
promote EMT indirectly. (B) β-catenin was found to exert a dual role as an essential cytoplasmic-
interaction partner of cadherins, which is essential for cell-cell adhesion, and as a nuclear partner of 
the T-cell factor (TCF)/lymphocyte-enhancer factor (LEF) family of transcription factors that regulate 
genes of the canonical Wnt signaling pathway. The switch of β-catenin from its action in cell adhesion 
to transcriptional control in the nucleus is controlled by binding to BCL9-2, which is the homologue of a 
human B-cell oncogene product, and is promoted by tyrosine phosphorylation of β-catenin (taken from 
(Birchmeier, 2005)). 
 
As already mentioned above, appropriate 
cell-cell adhesion requires the cadherin-catenin 
complex as a whole. Therefore, changes in the 
expression of catenins, for example mutations 
in α-catenin or expression of truncated α/β-
catenin, impair E-cadherin-mediated cell 
adhesion and are often associated with 
malignant transformation (Hajra and Fearon, 
2002; Hirohashi and Kanai, 2003). Recently it 
has been shown that knockdown of p120-
catenin results in the destruction of the entire 
cadherin complex (Reynolds and Roczniak-
Ferguson, 2004). Together with evidence of 
frequent p120-catenin loss in cancer, these 
observations suggest that p120-catenin 
downregulation itself may be an initiating event 
in a subset of E-cadherin-deficient tumors. 
However, direct evidence is lacking and it 
remains to be determined whether this would 
represent a general process in tumor 
progression. 
Proper E-cadherin function can also be 
overruled or replaced by the expression of 
mesenchymal cadherins, such as N-cadherin, 
which has been shown to promote cell motility 
and migration. It becomes more and more 
evident that this “cadherin switch” is involved 
during the transition from a benign to an 
invasive tumor phenotype (Christofori, 2003). 
Taken together, loss of E-cadherin-mediated 
cell-adhesion strongly contributes to tumor 
progression, but it is unlikely that loss of E-
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cadherin by itself can account for the 
metastatic phenotype, because loss of 
adhesiveness does not necessarily cause cells 
to become motile and/or invasive; additional 
events are required. 
 
1.2.3 E-cadherin-mediated signaling 
 
An increasing body of evidence suggests 
that cadherins act at the cellular level as 
adhesion-activated cell signaling receptors 
(Cavallaro and Christofori, 2004; Wheelock 
and Johnson, 2003). Although signals that are 
elicited by the formation of E-cadherin-
dependent cell-cell adhesion have been 
extensively studied, signals that are induced by 
the loss of E-cadherin function, for example 
during cancer progression, are only just being 
elucidated. 
Several studies have reported that 
establishment of E-cadherin-mediated contact 
influences the activity of Rho-family GTPases; 
with Rac and CDC42 being activated and Rho 
being inactivated. The mechanisms underlying 
this activation or inactivation vary depending 
on the model system used. One connection 
between cadherins and Rho GTPases is 
through p120-catenin. It has been shown that 
p120-catenin activates Rac1 and CDC42, 
perhaps by activating Vav2, which is a guanine 
exchange factor for these GTPases (Fig. 1.2.3) 
(Grosheva et al., 2001; Noren et al., 2001). 
Reynolds and colleagues showed that 
cytosolic p120-catenin inhibits RhoA activity by 
acting as guanine nucleotide dissociation 
inhibitor (Anastasiadis et al., 2000; Noren et 
al., 2000). It is worth noting that only cytosolic 
p120-catenin is able to modulate GTPase 
activity; this function is abolished when p120-
catenin participates in the E-cadherin adhesion 
complex. Rho activity decreases as cells 
become confluent, but as cytosolic p120-
catenin becomes sequestered by the E-
cadherin adhesion complex it cannot account 
for this decrease in Rho activity. Therefore, 
other mechanisms downstream of E-cadherin-
mediated adhesion decrease Rho activity. 
Noren et al. (Noren et al., 2003) reported that 
E-cadherin engagement in cell-cell adhesion 
suppresses Rho activity by inducing 
phosphorylation and activation of 
p190RhoGAP, probably through Src-family 
kinases. In other systems, E-cadherin was 
found to communicate with Rho GTPases via 
PI3K signaling (Fig. 1.2.3). PI3K is an 
upstream kinase of Rac and has previously 
been found to interact with E-cadherin (Pece et 
al., 1999; Woodfield et al., 2001). Yap and 
colleagues (Kovacs et al., 2002) showed that 
PI3K co-localized with E-cadherin at the 
leading edge of cadherin-based lamellipodia, 
and was necessary for full and sustained 
activation of Rac. In contrast, another group 
reported that Rac activation induced by E-
cadherin ligation was independent of PI3K 
activity, but dependent on EGFR signaling (see 
below) (Betson et al., 2002). Whatever the 
mechanisms are, E-cadherin-mediated 
contacts influence the activity of Rho-family 
GTPases, which are believed to regulate 
dynamic organization of the actin cytoskeleton 
and the activity of the cadherin/catenin 
apparatus to modulate stabilization of the 
adhesive contact (Yap et al., 1997). 
Several studies have suggested functional 
interdependence of cadherins and RTK with 
respect to their signaling capacities. It has 
been demonstrated that initiation of de novo E-
cadherin-mediated adhesive contacts can 
induce ligand-independent activation of the 
EGFR and subsequent activation of Erk 
(Munshi et al., 2002; Pece and Gutkind, 2000). 
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In contrast, it has been shown that the E-
cadherin adhesive complex can be linked to 
EGFR via β-catenin (Hoschuetzky et al., 1994) 
or via the extracellular domain of E-cadherin, 
and negatively regulate receptor tyrosine 
kinase signaling in an adhesion-dependent 
manner. Interaction of cadherins with 
respective RTK has been observed in different 
systems (VEGFR with VE-cadherin, and FGFR 
with N-cadherin) (Carmeliet et al., 1999; 
Cavallaro et al., 2001). 
It is worth noting that β-catenin, besides 
being a major component of the E-cadherin 
adhesion complex, is also part of the Wnt-
mediated signaling pathway. In the absence of 
Wnt signaling, cytosolic β-catenin is degraded 
through a pathway that is dependent on 
adenomatous poliposis coli protein (APC). 
However, upon stimulation of the Wnt pathway 
this degradation is suppressed, resulting in the 
accumulation of cytoplasmic β-catenin 
(Wheelock and Johnson, 2003). Subsequently, 
it translocates into the nucleus and acts as a 
coactivator of the T-cell factor 
(TCF)/lymphocyte-enhancer factor (LEF) 
transcription factors (Fig. 1.2.3). Given that 
binding to β-catenin precludes its participation 
in Wnt signaling, E-cadherin could potentially 
regulate Wnt signaling by sequestering β-
catenin from TCF/LEF transcription factors. 
Gumbiner and colleagues (Gottardi and 
Gumbiner, 2004) reported that the participation 
of β-catenin in adhesion and Wnt signaling is 
dictated by the presence of distinct molecular 
forms of β-catenin that have different binding 
properties. More recently it has been shown 
that this switch can be regulated by the binding 
of β-catenin to BCL9-2 (the homolog of the 
human B-cell oncogene product BCL-9). β-
catenin/BCL9-2 binding can be promoted by 
tyrosine phosphorylation of β-catenin, and 
competes with α-catenin binding and cell 
adhesion (Brembeck et al., 2004) (Fig. 1.2.2). 
Although some groups have shown that 
overexpression of E-cadherin fragments able 
to bind β-catenin can repress TCF/LEF 
transcriptional activity in 293T cells (Simcha et 
al., 2001) or SW480 cells (Gottardi and 
Gumbiner, 2004), another group was unable to 
find any dependence of TCF/LEF-mediated 
transcriptional activity on E-cadherin 
expression in human breast cancer cells (van 
de Wetering et al., 2001). The effects of E-
cadherin on Wnt signaling appear, therefore, to 
be cell-context-dependent. 
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Figure 1.2.3: Signaling by the E-cadherin complex. Initiation of de novo cell-cell adhesion activates 
Rac and CDC42, and inhibits Rho. Soluble p120-catenin and PI3K are most likely mediating these 
effects via activation of the respective guanine exchange factor (VAV) or GTPase-activating protein 
(p190RhoGAP). Establishment of E-cadherin-mediated contacts can also induce ligand-independent 
activation of the EGFR and, subsequently, activation of Erk and PI3K signaling. Cytosolic β-catenin is 
normally degraded through the adenomatous poliposis coli (APC) complex. However, WNT signaling 
inhibits the APC complex, allowing β-catenin to enter the nucleus and coactivate TCF/LEF 
transcription factors. By sequestering β-catenin from participation in the WNT signaling, the E-cadherin 
adhesion complex might also modulate WNT-induced transcription. 
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1.3 RNA interference: a new 
and powerful tool in molecular 
biology 
 
RNAi is a general term for sequence-specific 
gene repression induced by double-stranded 
RNAs (dsRNAs) that was initially discovered in 
plants. It was later observed in the animal 
model organism Caenorhabditis elegans that 
dsRNA triggered sequence-specific mRNA 
cleavage (Fire et al., 1998). It soon turned out 
that RNAi is not restricted to nematode and 
can be induced in Drosophila melanogaster 
(Kennerdell and Carthew, 1998), Trypanosoma 
(Ngo et al., 1998), and vertebrates (Elbashir et 
al., 2001a; Yang et al., 2001). 
During RNAi, long dsRNA molecules are 
processed into 19- to 23-nt RNAs known as 
small-interfering RNAs (siRNAs) that serve as 
guides for enzymatic cleavage of 
complementary RNAs (Elbashir et al., 2001b; 
Parrish et al., 2000; Zamore et al., 2000). In 
Drosophila and C. elegans, siRNAs can 
function as primers for an RNA-dependent 
RNA polymerase that synthesizes additional 
dsRNA, which in turn is processed into 
siRNAs, amplifying the effects of the original 
siRNAs (Lipardi et al., 2001; Sijen et al., 2001).  
In mammalian cells, the experimental use of 
RNAi with dsRNA has not been successful in 
most cell types because of non-specific 
responses elicited by dsRNA molecules longer 
than about 30 nt (Robertson and Mathews, 
1996). Tuschl and coworkers (Elbashir et al., 
2001a) discovered that transfection of 
synthetic 21-nt siRNA duplexes into 
mammalian cells effectively inhibits 
endogenous genes in a sequence-specific 
manner. These siRNA duplexes are too short 
to trigger the non-specific dsRNA responses, 
but they still cause destruction of 
complementary RNA sequences (Gitlin et al., 
2002).  
More recently, a large number of 
endogenous microRNA (miRNAs) was 
discovered. miRNAs are a specific class of 
small RNAs that are encoded in gene-like 
elements organized in a characteristic inverted 
repeat (Grishok et al., 2001; Reinhart et al., 
2000). Because the active forms of miRNAs 
and siRNAs are sometimes biochemically or 
functionally indistinguishable, they are 
classified based on their origins (Fig. 1.3). 
siRNAs are derived from long dsRNAs in the 
cytoplasm, whereas miRNA genes are 
transcribed by RNA polymerase II to generate 
long primary transcripts (pri-miRNAs) (Cai et 
al., 2004; Lee et al., 2004). In the nucleus, pri-
miRNAs are trimmed to release hairpin 
intermediates (pre-miRNAs) (Lee et al., 2002) 
by the RNase III type enzyme Drosha (Lee et 
al., 2003). pre-miRNAs then get exported to 
the cytoplasm (Bohnsack et al., 2004), where 
they are processed in a similar way to 
dsRNAs, the precursors of siRNAs. pre-
miRNAs and dsRNAs are processed by Dicer, 
the cytoplasmic RNase III type protein 
(Bohnsack et al., 2004; Hutvagner et al., 2001; 
Ketting et al., 2001) and cleaved into the short-
lived miRNA/siRNA duplexes, whose one 
strand is degraded by an unknown nuclease 
while the other strand remains as a mature 
miRNA/siRNA (Khvorova et al., 2003; Schwarz 
et al., 2003). The released miRNAs/siRNAs 
are incorporated into silencing complexes. 
Although it is difficult to assign a distinct 
functional label, an siRNA-containing complex 
is commonly referred to as RNA-induced 
silencing complex (RISC), whereas an miRNA-
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containing effector complex is referred to as a 
micro ribonucleoprotein particle (miRNP) 
(Meister and Tuschl, 2004). Every RISC or 
miRNP contains a particular subset of 
Argonaute proteins that exert sequence-
specific gene repression by inducing cleavage 
(‘slicing’) or, as in the case of several miRNPs, 
by eliciting a block to translation (Meister and 
Tuschl, 2004). 
miRNAs are often only temporarily 
expressed and seem to play a role in 
developmental processes. In mammals, miR-
181 is involved in the control of hematopoiesis 
through as yet unknown target(s) (Chen et al., 
2004). Mouse miR-196 miRNAs repress the 
expression of the hoxb8 gene, a transcription 
factor important during vertebrate 
developmental regulation (Yekta et al., 2004). 
Several reports have also shown that altered 
expression of specific miRNA genes 
contributes to the initiation and progression of 
cancer (Croce and Calin, 2005; Gregory and 
Shiekhattar, 2005; McManus, 2003). All these 
findings prove that miRNAs play important 
regulatory roles in animals by targeting the 
messages of protein-coding genes for 
translational repression or degradation. 
 
Figure 1.3: Model of small-RNA-guided post 
transcriptional regulation of gene expression. 
Primary miRNA transcripts are processed to miRNA 
precursors in the nucleus by the RNase-III-like 
enzyme Drosha. The miRNA precursor is 
subsequently exported to the cytoplasm by means of 
the export receptor exportin-5. The miRNA precursor 
is further processed by Dicer to siRNA-duplex-like 
intermediates. The duplex is unwound while 
assembling into miRNP/RISC. Mature miRNAs bind 
to Ago proteins, which mediate translational 
repression or cleavage of target mRNAs. Other 
sources of long dsRNA in the cytoplasm of a cell are 
viral RNAs, artificially introduced dsRNA, and 
genomic sense and antisense transcripts. Like 
miRNA precursors, long dsRNA is processed by the 
RNase III enzyme Dicer into 21-23 nucleotide 
dsRNA intermediates. Assisted by the RNA helicase 
Armitage and R2D2, the single-stranded siRNA-
containing RISC is formed. The stability of the 
dsRNA, and its recognition by Dicer, can be 
regulated by specific ADARs (deaminase) and the 
exonuclease ERI-1. DCR: Dicer-like protein, R2D2: 
dsRNA binding protein (taken from (Meister and 
Tuschl, 2004)). 
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In contrast, siRNAs are produced from 
dsRNAs that are synthesized from viruses, 
endogenously activated transposons, or 
repetitive sequences introduced by genetic 
engineering. Thus, siRNAs have been 
proposed to function in: (i) antiviral defense, (ii) 
silencing mRNAs that are overproduced or 
translationally aborted, and (iii) guarding the 
genome from disruption by transposons 
(Hannon, 2002; Mello and Conte, 2004; 
Tabara et al., 1999). In experimental research, 
siRNAs can efficiently and rapidly 
downregulate the level of an endogenous 
protein in mammalian cells. The use of siRNA 
therefore complements overexpression studies 
in tissue culture by providing a powerful tool to 
investigate loss-of-function of a given protein. 
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1.4 Research objectives 
 
Several reports have shown that Shc 
adaptor proteins are involved in MAPK 
activation induced by several growth factors. 
However, the contribution of each isoform in 
mediating this process is still not known. 
Moreover, are there other signaling pathways 
in which Shc might play a role, despite growth 
factor-induced signaling? The largest isoform, 
p66Shc, does not seem to be involved in MAPK 
activation, but whether it acts in a dominant 
negative manner or in a neutral way is still a 
matter of debate. Gene targeting of p66Shc has 
revealed that this isoform is implicated in the 
regulation of lifespan and the response to 
oxidative stress. The absence of p66Shc 
confers resistance to oxidative stress on 
mouse embryo fibroblasts, endothelial cells, 
and T-cells. Still, it is unclear whether this is a 
general effect or restricted to certain cell types 
and what the underlying mechanisms are.  
This thesis aims to address some of these 
questions. To investigate isoform-specific 
functions of Shc proteins, we first generated a 
system to specifically knockdown single Shc 
isoforms using siRNA. This method was 
developed further to the so-called “knockdown-
in system”, where we achieved an isoform-
specific expression of Shc proteins. These 
data will be discussed in greater detail in the 
first part of the following chapter.  
Secondly, we used this method to explore 
how necessary Shc proteins are in EGF-
induced signaling. In a quest for growth factor-
independent pathways in which Shc proteins 
might be involved, we investigated signaling 
downstream of the cell adhesion molecule, E-
cadherin. These results are described in 
sections 2.3-2.5. The last part of the following 
chapter represents data on the role of p66Shc in 
regulating cell viability upon stress response in 
epithelial cells. 
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2. RESULTS 
2.1 RESEARCH COMMUNICATION 
Isoform-specific knockdown and expression of adaptor protein ShcA using small 
interfering RNA 
Malgorzata KISIELOW1, Sandra KLEINER1, Michiaki NAGASAWA3, Amir FAISAL and Yoshikuni NAGAMINE  
Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66 CH-4058 Basel, Switzerland 
1 These authors contributed equally to the work. 
Many eukaryotic genes are expressed as multiple 
isoforms through the differential utilization of 
transcription/translation initiation sites or 
alternative splicing. The conventional approach for 
studying individual isoforms in a clean background 
(i.e. without the influence of other isoforms) has 
been to express them in cells or whole organisms in 
which the target gene has been deleted; this is time-
consuming. Recently an efficient post-
transcriptional gene-silencing method has been 
reported that employs a small interfering double-
stranded RNA (siRNA). On the basis of this 
method we report a rapid alternative approach for 
isoform-specific gene expression. We show how 
the adaptor protein ShcA can be suppressed and 
expressed in an isoform-specific manner in a 
human cell line. ShcA exists in three isoforms, 
namely p66, p52 and p46, which differ only in their 
N-terminal regions and are derived from two 
different transcripts, namely p66 and p52/p46 
mRNAs. An siRNA with a sequence shared by the 
two transcripts suppressed all of them. However, 
another siRNA whose sequence was present only in 
p66 mRNA suppressed only the p66 isoform, 
suggesting that the siRNA signal did not propagate 
to other regions of the target mRNA. The 
expression of individual isoforms was achieved by 
first down-regulating all isoforms by the common 
siRNA and then transfecting with an expression 
vector for each isoform that harboured silent 
mutations at the site corresponding to the siRNA. 
This allowed functional analysis of individual ShcA 
isoforms and may be more generally applicable for 
studying genes encoding multiple proteins. 
 
Key words: post-transcriptional gene silencing, 
RNAi, transient knockdown-in.
 
INTRODUCTION 
In eukaryotes, many genes encode multiple 
isoforms by way of differential 
transcription/translation initiation or alternative 
splicing, thus giving rise to related proteins with 
biochemically as well as biologically distinct 
features [1]. Although, in many cases, multiple 
isoforms are expressed in the same cell at the same 
time, the expression level and pattern of each 
isoform may vary with the cell type and its stage of 
development, making the study of each isoform 
confusing and difficult. Investigation of the 
function of individual isoforms ideally requires 
conditions where only one isoform is expressed or 
eliminated. While several protocols for tissue-
specific expression or elimination of the gene of 
interest have been developed [2–4], reports of 
isoform-specific gene inactivation [5] or expression 
in a clean background are limited. Such protocols 
are usually lengthy, often requiring several months 
to establish the desired conditions. During this time, 
cells or organisms may adapt to the new conditions 
[6] and caution is required when interpreting the 
results.  
The signalling adaptor/scaffold protein ShcA is a 
member of the Shc family, which consists of three 
genes, ShcA, ShcB/Sli/Sck and ShcC/N-Shc/Rai [7]. 
ShcA is ubiquitously expressed, whereas ShcB and 
ShcC are expressed specifically in the brain [8]. 
ShcA is recruited to, and phosphorylated by, 
activated receptor tyrosine kinases and, in turn, 
recruits the growth-factor-receptor-bound protein 2 
(Grb2)–Son-of-sevenless ('Sos') complex via the 
Src homology 2 (SH2) domain of Grb2, thus 
relaying growth-factor-induced signals to the 
Ras/extracellular-signal-regulated protein kinase 
('ERK') signalling pathway [9]. It is also involved 
in growth-factor-mediated activation of c-Jun N-
terminal kinase ('JNK') and protein kinase B, but 
the precise mechanism is unknown [9]. There are 
three isoforms of ShcA, namely p66ShcA, 
p52ShcA and p46ShcA, derived from a single gene 
through differential usage of transcription initiation 
sites and translation start sites, which differ only in 
the N-terminal regions [7]. While all three isoforms 
contain three tyrosine residues in the 
phosphotyrosine-binding (PTB) domain that are 
phosphorylated by activated receptor tyrosine 
kinases, they differ in the pattern of 
serine/threonine phosphorylation induced by 
growth factors and tumour phorbol esters. This 
suggests a different cellular function for each 
isoform ([5, 10]; A.F. El-Shemerly, A. Faisal and 
Y. Nagamine, results not shown). However, a 
systematic analysis of each isoform without the 
influence of other isoforms has not been reported.  
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Post-transcriptional gene silencing (PTGS) is a 
phenomenon originally reported in plants [11, 12], 
where introduction of the transgene causes 
silencing of the endogenous homologous gene and 
itself. The mechanism of PTGS involves enhanced 
mRNA degradation with double-stranded (ds)RNA 
as the trigger [13, 14]. A similar phenomenon 
(quelling) was observed in Neurospora [15]. In the 
Animal Kingdom, dsRNA-mediated gene silencing 
was first described in the nematode Caenorhabditis 
elegans [16] and was termed 'RNA interference' 
(RNAi). Subsequently, RNAi has been observed in 
a wide range of organisms, including flies, 
trypanosomes, Hydra, zebrafish (Danio rerio) and 
mice [13, 17]. The mechanism underlying RNAi 
has been partially elucidated, and a 21–23-nt-long 
dsRNA was found to be the intermediate/mediator 
of mRNA decay [18, 19]. Elbashir et al. [20] have 
shown recently that transfection of the 21-nt 
dsRNA, termed 'small interfering RNA' (siRNA), 
can trigger PTGS of both the co-transfected and the 
endogenous gene in cultured mammalian cells. In a 
cell-free system of dsRNA-mediated mRNA decay 
using Drosophila embryonal cell extracts, the 
mRNA was shown to be cleaved only within the 
region of identity with the dsRNA [18], suggesting 
that endonucleolytic cleavage induced by siRNA is 
very specific and that it is probably not propagated 
to other regions of mRNA. However, the interesting 
possibility of distinguishing closely related mRNAs 
by siRNA has not been addressed with mammalian 
cells. 
In the present study, using transient transfection 
assays in HeLa cells, we established that the target 
of siRNA is restricted to mRNAs containing the 
identical sequence. This facilitated the isoform-
specific knock-down of p66ShcA as well as 
isoform-specific expression of ShcA isoforms. 
 
EXPERIMENTAL 
 
Cells and transfection 
 
HeLa cells were cultured in Dulbecco's modified 
Eagle's medium (Gibco BRL) supplemented with 
10% (v/v) fetal-calf serum (AMIMED; BioConcept, 
Allschwil, Switzerland), 0.2mg/ml streptomycin 
and 50 units/ml penicillin at 37°C in a humidified 
5% CO2 incubator. A day before transfection with 
siRNA, cells were plated in six-well plates in 
medium without antibiotics at 1.4×10 5cells/well. 
The next morning, siRNAs were introduced into 
HeLa cells using the OLI GOFECT AMINE™ 
reagent (Life Technologies) according to the 
manufacturer's instructions, with 10µl of 20µM 
siRNA and 3µ l of transfection reagent/well. 
Transfection with expression vectors was carried 
out 2 days after the OLIG OFECTAMINE™ 
transfection using LIPOFE CTAMINE™ 2000 
(Life Technologies). 
 
cDNA cloning of ShcA isoforms 
 
The full-length mouse p46, p52 and p66ShcA 
cDNAs were isolated from NIH 3T3 cells by 
reverse transcriptase-PCR using the sense primers 
5´-CGG AAT TCA TGG GAC CTG GGG TTT 
CCT ACT-3´, 5´-CGG AAT TCA TGA ACA AGC 
TGA GTG GAG GCG-3´ and 5´-CGG AAT TCA 
TGG ATC TTC TAC CCC CCA AGC CGA AGT 
A-3´ respectively and the common antisense primer 
5´-CGG AAT TCA CAC TTT CCG ATC CAC 
GGG TTG C-3´. Full-length ShcA cDNAs were 
initially cloned into pBluescriptII KS+ and 
nucleotide sequences verified by the 
dideoxynucleotide-chain-termination procedure. 
 
Construction of expression vectors 
 
The haemagglutinin (HA)-tagged expression vector 
pcDNA3HA was constructed by inserting the 
overlapping oligonucleotide pair 5´-CCC ACC 
ATG GCT TAC CCA TAC GAT GTT CCA GAT 
TAC GCT G-3´ and 5´-AAT TCA GCG AAT TCT 
GGA ACA TCG TAT GGG TAA GCC ATG GTG 
GGG TAC-3´ into the KpnI–EcoRI site of pcDNA3 
(Invitrogen). To construct expression vectors for 
HA- tagged ShcA, p46HA, p52HA and p66HA, the 
full-length cDNAs of p46, p52 and p66 were 
inserted into the EcoRI–EcoRV site of 
pcDNA3HA. ShcA mutants in which potential 
internal initiation methionine codons were 
converted into leucine codons, thus expressing only 
the p66ShcA or 52ShcA forms, were created using 
the QuickChange site-directed mutagenesis kit 
(Stratagene). The overlapping oligonucleotide pair 
5´-CTC CTC CAG GAC CTG AAC AAG CTG 
AGT G-3´ and 5´-CAC TCA GCT TGT TCA GGT 
CCT GGA GGA G-3´ was used to mutate Met65 
(start site for p52) to leucine in p66HA, resulting in 
p66HA-ml. Another overlapping oligonucleotide 
pair, 5´-CCA ACG ACA AAG TCC TGG GAC 
CCG GGG-3´ and 5´-CCC CGG GTC CCA GGA 
CTT TGT CGT TGG- 3´, was used to mutate the 
initiation sites for p46 in both p66HA-ml and 
p52HA, resulting in p66HA-ML and p52HA-ML. 
Silent mutations were introduced into these vectors 
at the sites corresponding to h/m-shc siRNA as 
above using the overlapping oligonucleotide pair 
5´-GGG GTT TCC TAC TTG GTC CGC TAC 
ATG GGT TGT C-3´ and 5´-CAC AAC CCA TGT 
AG C GGA CCA AGT AGG AAA CCC C-3´ 
(mutated nucleotides underlined) to give p46HA-
sm, p52HA-ML-sm and p66HA-ML-sm (h/m-shc 
means that the sequence of siRNA is common to 
both human and mouse shc sequences). Note that 
proteins expressed from these vectors are identical 
with the parent proteins. 
 
Oligoribonucleotides 
 
The following 21-mer oligoribonucleotide pairs 
were used: h/m-shc siRNA from nt 677–697 (in the 
PTB domain), 5´-CUA CUU GGU UCG GUA 
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CAU GGG-3´ and 5´-CAU GUA CCG AAC CAA 
GUA GGA-3´; and p66-shc siRNA from nt 236–
256 [in the CH2 (collagen homology 2) domain], 
5´-GAA UGA GUC UCU GUC AUC GUC-3´ and 
5´-CGA UGA CAG AGA CUC AUU CCG-3´. 
Entire sequences were derived from the sequence of 
human p66ShcA mRNA (accession number 
HSU7377) and its complement and each pair has a 
3´ overhang of 2nt on each side. Designed RNA 
oligonucleotides were 'blasted' against the 
GenBank®/EMBL database to ensure gene 
specificity. The RNA oligonucleotides were 
obtained from Microsynth (Balgach, Switzerland). 
Annealing was performed as described by Elbashir 
et al. [ 20]. The complementary two strands (each at 
20µM) in 200µl of annealing buffer [100mM 
potassium acetate/30mM Hepes/KOH (pH 
7.4)/2mM magnesium acetate] were heated for 
1min at 90°C and then incubated for 1h at 37°C. An 
siRNA corresponding to nucleotides 753–773 of the 
firefly luciferase mRNA was used as a negative 
control. 
 
Western-blot analysis 
 
At the times indicated, cells were lysed in a buffer 
containing 120mM NaCl, 50mM Tris, pH 8.0, and 
1% Nonidet P40 plus Complete (Roche) protein 
inhibitor tablets. The whole-cell extracts (20 µg) 
were analysed by Western blotting using a 
polyclonal rabbit anti-Shc antibody (1:250; 
Transduction Laboratories), mouse monoclonal 
anti-Grb2 (1:1000; Transduction Laboratories) or a 
mouse monoclonal anti-b-tubulin antibody (1:1000; 
Sigma). We used anti-rabbit or anti-mouse 
horseradish peroxidase-linked antibodies from 
Amersham as secondary antibodies. An enhanced 
chemiluminescence (ECL®) detection method 
(Amersham) was employed, and the membrane was 
exposed to Kodak X-Omat LS film. Quantification 
of ShcA proteins was done using ImageQuant 5.0. 
 
RESULTS 
 
Efficient down-regulation of ShcA by siRNA 
 
Three isoforms of ShcA are derived from a single 
gene through differential usage of transcriptional 
initiation sites (p66 versus p52/p46) and 
translational initiation sites (p52 versus p46) ( 
Figure 1). The primary transcript of p52/p46 
mRNA contains the entire sequence of p66 mRNA; 
however, the very-5´ region of p66 mRNA is 
present in the first intron of p52/p46 mRNA, but is 
absent in the latter mRNA, having been spliced out. 
The p46 and p52 isoforms are derived from the 
same mRNA using different translation initiation 
sites. Target sites of two siRNAs used are shown in 
Figure 1 below the p66 ShcA mRNA. Note that the 
sequence of p66-shc siRNA is from a 5´ region of 
human p66ShcA mRNA and is absent in p52/46 
ShcA mRNA. 
When HeLa cells were transfected with the h/m-shc 
siRNA, the levels of all three ShcA isoforms were 
strongly decreased 24h after transfection and 
reached less than 20% of the control after 48h and 
4% after 60h (Figure 2A). The level of control 
protein (b-tubulin) was not affected under the 
conditions employed, and this was also the case for 
Grb2, a protein that specifically interacts with ShcA 
upon activation of growth-factor signalling [ 7]. 
Time-course analysis showed that the levels of all 
ShcA isoforms remained low until the fifth day 
after transfection, but started to increase thereafter ( 
Figure 2B). The decrease in the three isoforms was 
uniform, suggesting that both p52/p46 and p66 
ShcA mRNAs were equally targeted by the siRNA. 
 
Isoform-specific ShcA knockdown 
 
When cells were transfected with p66-shc siRNA, 
only the p66ShcA isoform was decreased, with 
kinetics similar to that obtained with h/m-shc 
siRNA; the other two isoforms were not affected ( 
Figure 3A and 3B). In another experiment, cells 
were challenged a second time with the same p66-
shc siRNA 6 days after the initial transfection, 
when the level of p66ShcA was very low, but about 
to increase, and 10 days after the initial 
transfection, when the level of p66ShcA recovered 
substantially. As shown in Figure 3 (C), the level of 
p66ShcA remained low and decreased markedly 
again after transfection at days 6 and 10 
respectively. 
 
Isoform-specific ShcA expression: transient 
knockdown-in (see below) 
 
The target site of p66-shc siRNA is in the 5´ region 
of p66 ShcA mRNA that is derived from the exon 
1´ and is absent in p52/p46 ShcA mRNA (see 
Figure 1). The results of the above experiments 
suggest that the effect of an siRNA is restricted to 
mRNAs containing a sequence identical with that 
of the siRNA used. Furthermore, there was no 
spreading effect of the siRNA signal, at least not 
towards the 3´ of the target site in the mRNA. 
Otherwise, the p46 and p52 isoforms would also 
have been down- regulated by p66-shc siRNA. We 
exploited this specificity to establish conditions 
under which ShcA would be expressed in an 
isoform-specific manner, which we call 'transient 
knockdown-in'. We constructed expression vectors 
encoding mouse ShcA isoforms with or without 
silent mutations at the region corresponding to h/m-
shc siRNA that left the protein sequences 
unchanged. Two point mutations were introduced 
into each expression vector so that it was not 
recognized by h/m-shc siRNA. Cells were first 
transfected with h/m-shc siRNA to knock-down all 
three isoforms and then 2 days later with an 
expression vector encoding each isoform of mouse 
ShcA. As shown in Figure 4, h/m-shc siRNA 
knocked down all three isoforms of endogenous 
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ShcA almost completely. Transfection of these cells 
with mutant expression vectors for individual 
isoforms resulted in the expression of only the 
corresponding isoforms. As expected, almost no 
protein was detected in cells transfected with wild-
type expression vectors. Cells which were not 
transfected with h/m-shc siRNA expressed elevated 
levels of ShcA isoforms, irrespective of the 
presence or absence of mutations in the expression 
vectors. 
 
Figure 1 Relationship between the ShcA gene, mRNA and protein. 
The gene and mRNA are drawn to the same scale. Two transcription 
initiation sites are indicated by arrows. The boxes of the gene represent 
exons. Exon 0 that is under control of the p52/p46 promoter is ligated to 
exon 1 after splicing. Exons 1’ and 1 are transcribed contiguously under 
the p66 promoter. Translation initiations sites are indicated both on the 
gene and mRNAs by triangles. The protein domains are demarcated 
and indicated: CH1 and 2, collagen homology 1 and 2; PTB, 
phosphotyrosine binding; and SH2, Src homology 2. The two siRNAs 
used in this work are indicated below p66 mRNA.  
Figure 2 Knock-down of ShcA in HeLa cells. 
 
Cells were transfected using the oligofectAMINE™ reagent without 
siRNA (-) or with h/m-shc siRNA (S) and firefly luciferase siRNA (L). At 
different times after transfection, whole-cell extracts were prepared and 
analysed by Western blotting as described in the Experimental section. 
Membranes were probed for Shc, β-tubulin and Grb2. (A) Specificity; 
(B) time course. 
Figure 3 Isoform-specificknockdown  
 
(A) p66-selective knock-down. Cells were untreated or 
transfected without siRNA (-) or with h/m-shc siRNA (S), p66-shc siRNA 
(66) and control firefly luciferase siRNA (L). Whole-cell extracts were 
prepared 48h later and analysed for ShcA and b-tubulin levels as in 
Figure 2. (B) Time course. Cells were transfected with p66-shc siRNA 
or luc siRNA and the levels of ShcA proteins were analysed at different 
times as above. (C) Repeated transfection. On days 6 (white triangle) or 
10 (black triangle) after the first transfection, cells were transfected 
again with the same p66-shc siRNA. The levels of ShcA and control b-
tubulin proteins were analysed at different times as above. 
Abbreviation: luc siRNA, firefly luciferase mRNA. 
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Figure 4 Isoform-specific expression of ShcA  
 
Cells were first transfected with no siRNA (mock) or with h/m-shc siRNA to down-regulate endogenous ShcA proteins. After 2 days, the cells were 
transfected with an empty expression vector, pCDNA3, or an expression vector for each isoform of wild-type (-wt) and silent mutant (-sm) ShcA. A day later, 
whole-cell extracts were prepared and analysed by Western blotting for the ShcA expression level. Membranes were blotted with polyclonal anti-ShcA and 
anti-b-tubulin antibodies. 
 
DISCUSSION 
In the present study we have shown that siRNA can 
efficiently, specifically and rapidly down-regulate 
the level of an endogenous protein in mammalian 
cells. The effect of siRNA was restricted to mRNAs 
containing a sequence identical with that of the 
siRNA used. That the primary action of siRNA on 
mRNA, which is most likely an endonucleolytic 
attack, does not propagate to other regions of the 
target mRNA was inferred from the following 
observations: (1) the effect of p66-shc siRNA was 
restricted to p66ShcA ( Figure 3) and (2) h/m-ShcA 
siRNA targeted wild-type ShcA, but not mutant, 
mRNAs ( Figure 4). In the first observation, 
expression of p52/p46 ShcA was not affected, 
although p66 and p52/p46 mRNAs shared sequence 
identity in most of the region 3´ of the siRNA site 
(see Figure 1), indicating that the silencing signal 
does not propagate to regions of mRNA 3´ to the 
siRNA. The second observation was with 
ectopically expressed ShcA mRNAs. In this 
experiment, sequences of wild-type ShcA mRNA 
and mutant ShcA mRNA for each isoform were 
identical, except for two nucleotides at the siRNA 
recognition site located in the middle of the mRNA. 
If the silencing signal did spread either 5´ or 3´ of 
the siRNA, ShcA expression from both wild-type 
and mutant mRNAs would have been suppressed. 
That expression from wild-type mRNAs but not 
from mutant mRNAs was suppressed strongly 
argues for stringent specificity of siRNA-mediated 
mRNA decay. This possibility was already 
suggested indirectly by Zamore et al. [ 18]. Using 
cell-free decay reactions containing insect cell 
lysates and dsRNA, they showed cleavage of target 
mRNA only within the region corresponding to the 
dsRNA. However, this analysis was only on the 
primary action of dsRNA-mediated mRNA 
cleavage and did not consider the possibility of 
signal amplification taking place in vivo. Indeed, 
results of experiments in an insect cell- free system 
[ 21] and C. elegans [ 22] have led to the suggestion 
that long dsRNA molecules synthesized by RNA-
dependent RNA polymerase are intermediates in 
RNAi that amplify and maintain the effect of 
siRNA. This implies 5´ spreading of the silencing 
signal from siRNA. Our finding in HeLa cells that 
siRNA-mediated RNAi does not propagate to 
homologous regions of the target RNA suggests 
that this may not be the case in mammalian cells. 
Moreover, no endogenous RNA-dependent RNA 
polymerase has been reported in mammalian cells, 
except after RNA virus infection [ 23]. This may 
also explain why there is no systemic PTGS in 
mammals, which requires the amplification of 
siRNA, as has been often observed in other 
Kingdoms [ 16, 24]. Also, if amplification is 
involved in silencing in mammalian cells, antisense 
RNA oligonucleotides alone should serve as a 
primer for RNA-dependent RNA polymerase and 
thus be sufficient for gene down-regulation. We 
found that antisense RNA did not induce silencing 
(results not shown), in agreement with the previous 
report by Tuschl et al. [ 25]. Thus it may be a 
unique feature of mammalian cells that the 
silencing signal spreads neither 5´ nor 3´ of the 
siRNA, restricting the action of siRNA to mRNAs 
that carry a sequence identical with that of siRNA. 
An important implication of our results is that the 
combination of PTGS using siRNA and the 
isoform-specific expression of an homologous gene 
with silent mutations, which we call transient 
knockdown-in, causes the cell to express only one 
isoform, while keeping the levels of other isoforms 
very low. Using the transient knockdown-in 
method, it should be possible to examine the effect 
of various mutations of individual isoforms on 
cellular activity. The critical point in this method is 
that expression vectors should be designed so that 
they are not recognized by siRNA. Two 
mismatches in the mutated expression vectors were 
sufficient for them to be exempted from siRNA-
mediated suppression ( Figure 4). We used 
expression vectors for mouse ShcA in the present 
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study because there is a high degree of sequence 
similarity between mouse and human ShcA (90% 
mRNA sequences and 93% amino acid sequences 
for p66 isoform). Thus, instead of introducing 
mutations into expression vectors, it would have 
been possible to design a different siRNA with a 
sequence matching perfectly the endogenous 
human ShcA gene, but not the transfected mouse 
gene, and achieve similar results. The advantage of 
our approach, however, is that we can obtain 
isoform-specific ShcA expression in both human 
and mouse cells using the same set of probes. 
The sequence of p66-shc siRNA is present in the 
primary transcripts of p52/p46 ShcA mRNA, but is 
spliced out of the mature mRNA (see Figure 1). 
The fact that only the p66 ShcA isoform was down-
regulated by p66-shc siRNA strongly suggests that 
the site of action of siRNA is confined to the 
cytoplasm. If siRNA acted in the nucleus and 
triggered the decay of transcripts containing the 
corresponding sequence, the p52ShcA and 
p46ShcA proteins should have been equally down-
regulated by the same p66-shc siRNA. Whether 
siRNA can enter the nucleus is not known. Even if 
it does so, it would be able to access to mRNA only 
after completion of its processing to mature mRNA. 
The response of cells to ShcA siRNA was rather 
fast and efficient; the target ShcA isoforms were 
already greatly decreased within 24h of transfection 
(>60%), and the protein levels remained low until 5 
days after transfection. After 5 days, the reduced 
ShcA isoforms started to increase. There are two 
possibilities to account for this reappearance of the 
down-regulated isoforms: (1) adaptation of the cells 
to the siRNA by establishment of a resistant 
mechanism; or (2) dilution or degradation of siRNA 
with time. Because repeated transfection 
maintained or re-established the low levels of target 
ShcA isoform ( Figure 3B), the latter simple 
dilution/degradation mechanism seems to apply. 
While a period of 5 days of down-regulation by a 
single transfection is long enough for some 
biochemical analysis, repeated transfection should 
allow long-term experiments. Repeated transfection 
will be necessary where the target protein has a 
slow turnover. 
In summary, we have shown in mammalian cells 
that the site of action of siRNA-mediated mRNA 
degradation is confined to the cytoplasm and that 
the target mRNA is restricted to those mRNAs 
containing a sequence identical with that of the 
siRNA used. These specific features of siRNA-
mediated gene knock-down can be employed over a 
short time period in conjunction with specific 
expression vectors to establish conditions for 
expression of the ShcA gene in an isoform-specific 
manner. This knockdown-in method should be 
applicable and useful for the study of genes 
expressed as multiple isoforms. 
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2.2 Using siRNAs to study Shc 
function  
 
2.2.1 Isoform-specific knockdown of 
p46/52Shc 
 
As described before, siRNA transfection 
allowed the knockdown of all Shc isoforms 
and, the specific knockdown of p66Shc. In the 
next step we generated siRNA to specifically 
knockdown p46/52Shc. The 3’ end of the 
p46/52Shc mRNA contains exon 1 which is not 
translated and, more importantly, not present 
in the p66Shc mRNA (Fig 2.2.1A). Transfection 
of siRNA targeting this region (si-p46/52Shc) 
specifically reduced the protein levels of p46Shc 
and p52Shc, but did not change the amount of 
p66Shc (Fig 2.2.1B).  
 
2.2.2 Growth inhibition upon Shc 
knockdown 
 
To develop the isoform-specific knockdown 
and the knockdown-in system, all experiments 
were done using 100 nM siRNA, based on an 
earlier study involving siRNA-mediated 
knockdown of genes in human cells (Elbashir 
et al., 2001a). As a control for specificity, cells 
were transfected with siRNA targeting the 
luciferase gene (si-luci), which is not 
expressed in the cells, or with no siRNA 
(buffer) (Fig 2.2.1B). During the course of the 
experiments, we noticed that knockdown of 
Shc isoforms negatively influenced the growth 
of HeLa cells. While transfection without any 
siRNA (buffer) and with siRNA targeting the 
luciferase gene did not impair the proliferation 
of HeLa cells, transfection with Shc-targeting 
siRNAs reduced the growth of the cells (Fig 
2.2.2-1A). This effect was strongest after 
knockdown of all Shc isoforms (si-shc1), and 
seemed to be milder after knockdown of only 
p66Shc or p46/p52Shc. To see whether the 
observed effect is due to Shc knockdown, a 
second siRNA (si-shc2) which targets a 
different region in the mRNA of all Shc 
isoforms was used. Upon transfection with si-
shc2, HeLa cell proliferation was reduced to a 
similar extent to si-shc1, when measured using 
an MTT proliferation assay (Fig 2.2.2-1B).
 
Figure 2.2.1: Isoform-specific knockdown of Shc A. Schematic representation of p46/52Shc and 
p66Shc mRNA. The triangles point to the ATG start codons, and the black boxes indicate the site 
targeted by the siRNA. B. HeLa cells were transfected with different siRNAs and collected three days 
later. Total cell lysate was used for Western blot analysis to probe for Shc and β-tubulin levels. B: 
buffer; L: si-luci; S: si-shc1; 46/52: si-p46/52shc; 66: si-p66shc. 
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Figure 2.2.2-1: Transfection of Shc siRNA inhibits growth in HeLa cells. A. HeLa cells were 
transfected with different siRNAs as indicated. Three days later pictures were made using light 
microscopy. B. HeLa cells were transfected with si-shc1 (S1), si-shc2 (S2), or si-luci (L) and 
proliferation was measured after three days using an MTT proliferation assay: additionally, total cell 
lysate was used for Western blot analysis. 
 
We next investigated whether this growth 
inhibition is a general effect which can also be 
observed in other cell types. As depicted in 
Fig. 2.2.2.-2, knockdown of all Shc isoforms 
inhibited proliferation in PNT2 cells, PC3 cells, 
and LLC-PK1 cells that do not express p66Shc.  
To investigate which Shc isoform was 
responsible for the growth inhibitory effect and 
would be able to rescue it, the knockdown-in 
system was used. LLC-PK1 and HeLa cells 
were generated to stably express single Shc 
isoforms which carry a silent mutation in the 
region targeted by the siRNA. These cells were 
subsequently used to knockdown the 
endogenous Shc proteins, and proliferation 
was measured by MTT assay. Expression of 
p52Shc did not rescue proliferation in HeLa or 
LLC-PK1 cells (Fig 2.2.2-3A). Moreover, 
expression of siRNA-resistant p46Shc in 
addition to p52Shc also did not prevent the 
growth-inhibitory effect caused by the siRNA in 
LLC-PK1 cells, although the Shc expression 
level was completely rescued (Fig 2.2.2-3B). 
These experiments demonstrated that the 
effect of siRNA transfection on proliferation 
was not dependent on Shc protein levels, but 
presented rather an unspecific response. 
  RESULTS 
 41 
 
Figure 2.2.2-2: Transfection of Shc siRNA inhibits growth in PNT2, PC3, and LLC-PK1 cells. 
Cells were transfected with si-shc1 (S) or si-luci (L), and three days later proliferation was measured 
using an MTT assay and total cell lysate was analyzed by Western blotting. 
 
 
Figure 2.2.2-3: Growth inhibition caused by si-shc is an unspecific effect. Stable HeLa or LLC-
PK1 cell lines expressing an empty vector or silent mutants of HA-p52shc (p52shcsm) (A) and HA-
p46/52Shc (only LLC-PK1) (B) were prepared and transfected with siRNA targeting all Shc isoforms (S) 
or luci siRNA (L). After three days of transfection, proliferation was measured using an MTT assay and 
total cell lysate was analyzed by Western blotting. 
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To avoid unspecific events for future 
experiments, the minimum amount of siRNA 
sufficient for efficient knockdown was 
determined. Fig. 2.2.2-4A shows that 
knockdown using only 10 nM siRNA reduced 
Shc protein levels as effectively as knockdown 
using 100 nM siRNA. Moreover, almost no 
effect on proliferation was observed after 
transfection with 10 nM si-shc when compared 
to buffer transfection or transfection with a 
scrambled control si-RNA in LLC-PK1 and 
MCF7 cells (Fig. 2.2.2-4B, C).  
In conclusion, to study the function of 
proteins using siRNA only low concentrations 
of siRNA should be used to avoid unspecific 
effects, and rescue experiments should be 
performed to ensure specificity. 
 
 
Figure 2.2.2-4 Knockdown of Shc using 10 nM siRNA. A. Indicated amounts of si-shc1 were 
transfected into LLC-PK1 cells and, three days after transfection, total cell lysate was analyzed by 
Western blotting. B, C. LLC-PK1, MCF7, and a stable MCF7 cell line expressing HA-p52Shc were 
transfected with buffer, si-shc1, or si-control. Proliferation was measured by counting cells with the Vi-
CELL analyzer. 
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2.3 Role of Shc in EGF-induced 
signaling in epithelial cells 
 
2.3.1 Role of Shc in EGF-induced 
Erk activation 
 
Shc has been shown to be involved in EGF-
induced Erk activation (1.1.2). However, the 
contribution of each Shc isoform to this event 
has not been investigated. In addition, it is still 
unclear whether p66Shc influences Erk 
activation in a dominant negative manner. The 
isoform-specific knockdown and the 
knockdown-in system provide perfect tools for 
investigating this question. Surprisingly, 
knockdown of either all Shc isoforms or only 
p66Shc did not affect EGF-induced Erk 
activation at any timepoint in HeLa cells (Fig 
2.3.1A right panel). In addition, knockdown of 
any Shc isoform did not influence EGF-induced 
Erk activation in the epithelial cell lines PNT2 
(Fig 2.3.1B left panel), PC3, and LLC-PK1 
(data not shown). Results with Shc-deficient 
MEFs suggest that Shc sensitizes cells to low 
amounts of growth factors. Therefore, siRNA-
transfected HeLa and PNT2 cells were treated 
with low concentrations of EGF in the next 
experiment. EGF-induced Erk activation was 
reduced by low amounts of EGF; however, Shc 
knockdown had no influence in both HeLa and 
PNT2 cells (Fig 2.3.1B).  
 
 
Figure 2.3.1: Effect of Shc knockdown on EGF-induced Erk activation. Cells were transfected 
with siRNA and treated three days later with 50 ng/ml EGF for the indicated time (A) or for 10 min with 
the indicated EGF concentration (B). Total cell lysate was subjected to Western blot analysis. U: 
untreated; B: buffer; L: si-luci; S: si-shc1; 66: si-p66Shc; 46/52: si-p46/52Shc. 
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2.3.2 Effect of p66Shc on EGF-driven 
proliferation and cell survival 
 
MCF7 epithelial breast cancer cells express 
p66Shc at a very low level. Some reports 
suggest that reduced p66Shc expression may 
play a role in breast cancer, which is often 
driven by signaling from the EGFR family 
(Stevenson and Frackelton, 1998; Xie and 
Hung, 1996). Since p66Shc might negatively 
influence Erk signaling downstream of EGFR 
family members, it is intriguing to speculate 
that p66Shc reduces EGF-driven proliferation or 
survival. To investigate p66Shc function in 
MCF7 cells, stable cell lines overexpressing 
HA-p66Shc were generated. In addition, empty 
vector-expressing cells or cell clones 
overexpressing HA-p46Shc or HA-p52Shc were 
made as a control (Fig 2.3.2-1).  
 
Figure 2.3.2-1: MCF7 cells stably 
overexpressing Shc isoforms. MCF7 cells 
were stably transfected to overexpress HA-
p46Shc, HA-p52Shc, and HA-p66Shc. The clones 
depicted here were used for further 
experiments. 
 
The responsiveness to EGF-driven 
proliferation or viability of these cell clones was 
then investigated. Proliferation under starvation 
conditions without EGF was slowed down in all 
cell clones (Fig. 2.3.2-2A). The addition of 50 
ng/ml EFG to the starvation medium enhanced 
proliferation in all cell clones. Although these 
cell clones exhibited different proliferation 
rates, there was no consistency with respect to 
p66Shc expression. We also tested other clones 
(data not shown), but the proliferation rate 
seemed to be clone-dependent, rather than 
dependent on the expression of Shc isoforms. 
The same result was observed for cell viability, 
which started to decline 4 days after starvation 
in the absence of EGF. However, EGF 
treatment restored cell viability in all cell 
clones, independent of their p66Shc expression 
level (Fig. 2.3.2-2B), suggesting that neither 
EGF-induced proliferation nor cell survival was 
influenced by the expression of p66Shc in 
MCF7 cells.  
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Figure 2.3.2-2: Effect of p66Shc overexpression on EGF-mediated proliferation and survival. 
Stably transfected MCF7 cells expressing empty vector, HA-p66Shc, or HA-p52Shc were seeded, and 
from the next day (day 0) starved in medium containing 0.1 % FCS. Alternatively, 50 ng/ml EGF was 
added to the starvation medium. At days 0, 2, and 4 after starvation, cells were counted and viability 
was measured using trypan blue exclusion with VI-CELL analyzer. 
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Loss of E-cadherin-mediated cell-cell 
adhesion and expression of proteolytic 
enzymes characterize the transition from 
benign lesions to invasive, metastatic tumor, a 
rate-limiting step in the progression from 
adenoma to carcinoma in vivo. A soluble E-
cadherin fragment recently found in the 
serum and urine of cancer patients has been 
shown to disrupt cell-cell adhesion and to 
drive cell invasion in a dominant-interfering 
manner. Physical disruption of cell-cell 
adhesion can be mimicked by the function-
blocking antibody Decma. We have shown 
previously in MCF7 and T47D cells that 
urokinase-type plasminogen activator (uPA) 
activity is upregulated upon disruption of E-
cadherin-dependent cell-cell adhesion. We 
explored the underlying molecular 
mechanisms and found that blockage of E-
cadherin by Decma elicits a previously 
undescribed signaling pathway downstream 
of E-cadherin that leads to Src-dependent Shc 
and Erk activation and results in uPA gene 
activation. siRNA-mediated knockdown of 
endogenous Shc and subsequent expression of 
single Shc isoforms revealed that p46Shc and 
p52Shc but not p66Shc were able to mediate Erk 
activation. A parallel pathway involving PI3K 
contributed partially to Decma-induced Erk 
activation. This report describes that 
disruption of E-cadherin-dependent cell-cell 
adhesion induces intracellular signaling with 
the potential to enhance tumorigenesis and, 
thus, offers new insights into the 
pathophysiological mechanisms of tumor 
development. 
 
Tumor cell invasion, a key event of metastatic 
progression, requires spreading of tumor cells 
from the primary tumor. This is strongly 
dependent on the loss of homotypic cell-cell 
adhesion. E-cadherin is an important component 
of the cell-cell adhesion complex and required 
for the formation of epithelia in the embryo and 
the maintenance of the polarized epithelial 
structure in the adult (2). As a single-span 
transmembrane-domain glycoprotein, E-cadherin 
mediates cell-cell adhesion via calcium-
dependent homophilic interaction of its 
extracellular domain (3). Proteins such as p120-
catenin, α-catenin and β-catenin assemble the 
cytoplasmic cell adhesion complex on its 
intracellular domain and link E-cadherin 
indirectly to the actin cytoskeleton (3). 
E-cadherin is considered to be an important 
tumor suppressor (2,4). In vitro studies have 
clearly established a direct correlation between a 
defect in functional E-cadherin expression at the 
cell surface and the acquisition of an invasive 
phenotype (3). Moreover, a partial if not 
complete reversal of the invasive phenotype 
could be achieved by ectopic expression of E-
cadherin (3,5). While E-cadherin expression is 
maintained in most differentiated carcinomas, 
there is a strong correlation in several types of 
cancer, including breast, gastric, prostate, and 
colon carcinoma, between loss of E-cadherin 
expression and aggravated phenotypes, e.g. 
metastasis and malignancy leading to a poor 
survival rate (4). Loss of E-cadherin-mediated 
cell-cell adhesion occurs through various 
mechanisms, such as downregulation of E-
cadherin expression via promoter 
hypermethylation (6), transcriptional repression 
(7), E-cadherin gene mutation (7), modification 
of β-catenin (8), or the cleavage of E-cadherin by 
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matrix metalloproteases (MMPs) (9). Cleavage 
of E-cadherin results not only in the disruption of 
cell-cell adhesion but also in a soluble 80-kDa E-
cadherin fragment that itself disrupts cell-cell 
adhesion in a dominant-interfering manner, 
thereby promoting tumor progression (10). 
However, the intracellular processes subsequent 
to disruption of cell-cell adhesion remain elusive.  
Tumor metastasis involves, in addition to the 
loss of cell-cell adhesion, degradation of the 
extracellular matrix. MMPs and urokinase-type 
plasminogen activator (uPA) are known to be 
involved in extracellular matrix degradation. 
Moreover, increased expression of uPA is 
directly related to higher tumor growth and 
metastasis (1). Several analyses have already 
made it clear that the expression of E-cadherin 
and the expression of MMPs are inversely 
correlated (11,12) and that E-cadherin-dependent 
cell-cell contact regulates the expression of 
MMPs and uPA in vitro (13-15). However, the 
underlying molecular mechanisms are not yet 
fully understood. Expression of genes for these 
proteolytic enzymes can be induced by various 
stimuli, including growth factors and integrin 
ligation, and has often been shown to be Erk-
dependent (16-18). The adaptor protein ShcA, 
which is referred to here as Shc, is involved in 
coupling receptor and non-receptor tyrosine 
kinases to the Ras/extracellular regulated kinase 
(Erk) pathway (19). Shc is expressed in three 
different isoforms, p46Shc, p52Shc and p66Shc, but 
only the two smaller isoforms seem to be 
involved in Erk activation (20). Receptor 
tyrosine kinases activated by tyrosine 
phosphorylation recruit and phosphorylate these 
Shc isoforms. This creates a binding site for 
Grb2 and results in the recruitment of the 
Grb2/Sos complex to the vicinity of Ras, where 
Sos acts as a GTP exchange factor for Ras. 
An increasing body of evidence suggests that 
cadherins act at the cellular level as adhesion-
activated cell signaling receptors (3). Indeed, 
homophilic ligation of the E-cadherin 
ectodomain induces activation of several 
signaling molecules, such as Rho-family 
GTPases (3), MAPKs (22) and PI3K (3). These 
signals are believed to regulate dynamic 
organization of the actin cytoskeleton and the 
activity of the cadherin/catenin apparatus to 
support stabilization of the adhesive contact (23). 
Several studies have suggested functional 
interdependence of cadherins and receptor 
tyrosine kinases with respect to their signaling 
capacities. It has been shown that initiation of de 
novo E-cadherin-mediated adhesive contacts can 
induce ligand-independent activation of the EGF 
receptor (EGFR) and subsequent activation of 
(Erk) (22) (14). Moreover, it was shown that the 
E-cadherin adhesive complex can be linked 
directly to EGFR via the extracellular domain of 
E-cadherin and negatively regulate receptor 
tyrosine kinase signaling in an adhesion-
dependent manner (24).  
We have shown previously that disruption of E-
cadherin-dependent cell-cell adhesion with the 
function-blocking antibody Decma (also termed 
Uvomorulin antibody or anti- Arc-1) results in 
disruption of cell-cell adhesion of T47D and 
MCF7 breast cancer cells (25). The loss of the 
epithelial morphology was associated with an 
increased secretion of uPA into the extra cellular 
milieu. Furthermore, Decma treatment induced 
invasiveness into collagen which was inhibited 
by the addition of uPA antibodies. The enhanced 
uPA secretion was dependent on transcription 
(25). It appears therefore that disruption E-
cadherin-dependent cell-cell adhesion initiates 
signaling events leading to the uPA gene. 
However, the nature of these signaling events 
has remained largely unknown. Since both 
disruption of E-cadherin-dependent cell cell-
adhesion and the expression of uPA are causally 
involved in tumor progression, the understanding 
of these underlying intracellular events is of 
paramount importance. In the present study, we 
explored the signaling pathway linking 
perturbation of E-cadherin-dependent cell-cell 
adhesion to the activation of Erk and the uPA 
gene expression. 
 
MATERIALS AND METHODS 
 
Reagents - Decma and HA antibodies were 
used as a hybridoma supernatant (containing 
approximately 40-50 µg/ml antibody) dialyzed 
against DMEM (Mr cutoff 1.2×104). The Decma 
hybridoma cell line was kindly provided by D. 
Vestweber and R. Kemler. The dialyzed 
counterpart was used for control treatments. 
Unless indicated otherwise, cells were treated for 
30 min with Decma supernatant (40-50 µg/ml 
antibody) or control supernatant. Anti-Shc 
polyclonal, anti-Grb2, anti-E-cadherin 
monoclonal (used for Western analysis and 
immunostaining), and antiphospho-Src (Tyr-416) 
polyclonal antibodies were obtained from 
Transduction Laboratories. Antiphospho-PKB 
(Ser 473) and antiphospho-Erk polyclonal 
antibodies were from Cell Signaling, and anti-
Erk polyclonal, anti E-cadherin (sc-8426) (E-
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cad2) and anti-EGFR (sc-101) monoclonal 
antibody were obtained from Santa Cruz. Mouse 
monoclonal HA antibodies (12CA5) used for 
Western blotting or immunoprecipitation were 
purified on a protein A-Sepharose column and 
monoclonal antibodies against phosphotyrosine 
(4G10) were used as hybridoma supernatant. 
Anti-Src mouse monoclonal antibody (clone 327) 
was a gift from K. Ballmer-Hofer (Paul Scharrer 
Inst.). SB203580 and CGP77675 were kindly 
provided by E. Blum (Novartis AG), 
Wortmannin, UO126 and Y27634 were obtained 
from Calbiochem, LY294002 and Cytochalasin 
D (CytD) was from Sigma, SP600125 was 
obtained from Biomol, and TPA, horseradish 
peroxidase-conjugated anti-mouse and anti-
rabbit antibodies, ECL reagent, protein A and G-
Sepharose were from Amersham Bioscience.  
Cells and transfection - MCF7 and T47D 
cells were cultured in DMEM/HAMs F12 
(Invitrogene) supplemented with 10% FCS, 0.2 
mg/ml streptomycin, and 50 units/ml penicillin at 
37°C in a humidified incubator with 5% CO2. 
For plasmid transfection, T47D cells 
(0.7×106/well) were seeded in 6-well tissue 
culture plates and incubated overnight. Plasmid 
DNA (1 µg ) was transfected using 5 µl 
Lipofectamine 2000 according to the 
manufacturer’s instructions. Fugene 6 was used 
to transfect MCF7 cells (0.5×106/well). Plasmid 
DNA (1 µg) was incubated with Fugene 6 (ration 
2:3) for 20 min and the whole mixture was added 
to the cells, which were then incubated overnight 
at 37°C. For siRNA transfection, T47D cells 
(0.18×106/well) and MCF7 cells (0.12×106/well) 
were seeded and transfected the next day with 10 
nM siRNA as described (26) using 5 µl and 3 µl 
Oligofectamine, respectively. MCF7 cells 
expressing siRNA against E-cadherin or mouse 
NCAM were generated by the stable transfection 
of the pSuper retro vector containing the 
respective sequences. These cell lines were 
kindly provided by F. Lehembre and G. 
Christofori and details will be published 
elsewhere.  
Plasmids and siRNAs - Construction of 
expression vectors for HA-tagged full-length 
mouse p46shc, p52shc, and p66shc and the 
introduction of silent mutations by site-directed 
mutagenesis were described previously (26).The 
uPA-reporter plasmid pGL-2-puPA-4.6 was 
described previously (27). The following 21-mer 
oligoribonucleotide pairs (siRNAs) were used: 
shc siRNA nt 677–697 (in the protein tyrosine 
binding domain), 5´-CUA CUU GGU UCG 
GUA CAU GGG-3´ and 5´-CAU GUA CCG 
AAC CAA GUA GGA-3´; control siRNA 5'-
GUA CCU GAC UAG UCG CAG AAG-3' and 
5’-UCU GCG ACU AGU CAG GUA CGG-3’. 
The specificities of these sequences were 
confirmed by blasting against the 
GenBank/EMBL database. 
Immunoprecipitation and Western blot 
analysis - Immunoprecipitation and Western 
blotting were performed as described (28). 
RNA isolation and Northern blot analysis - 
MCF7 cells (0.5×106/well) were seeded in 6-well 
tissue culture plates. After 2 days, cells were 
treated as indicated, total RNA was isolated and 
10µg aliquots subjected to Northern blot analysis 
as described (27). 
Immunofluorescence - Immunostaining and 
microscopy were carried out as described 
previously (28). Briefly, cells were cultured on a 
cover slip, fixed in 1 ml of pre-warmed 3% 
paraformaldehyde in PBS for 20 min at room 
temperature, permeabilized with 0.5% Triton X-
100 in PBS for 10 min, blocked with 5% normal 
goat serum for 20 min, incubated with anti-E-
cadherin antibody (1:200) for 2 h, washed 3 
times with PBS, incubated 45 min with Alexa 
488 (1:500) and washed again 3 times. Finally, 
the cover slips were mounted on glass slides with 
Flouromount-G (Southern Biotechnology 
Associates Inc). Fluorescence was visualized 
with a Zeiss Axioplan fluorescence microscope 
(63X oil objective with, numerical aperture of 
1.4) and all images were captured using 
Axiovision 3.0 software. 
 Reporter gene assay (dual-luciferase-
assay) - Cells (5x105) were plated in a 6-well 
dish to be co-transfected the next day with the 
reporter plasmid and the Renilla control plasmid 
using Fugene 6. One day after transfection, cells 
were pretreated for 45 min with the indicated 
inhibitors and afterwards with Decma for 5 h 
before harvesting. Luciferase expression was 
measured according to the given protocol (Dual-
Luciferase Reporter Assay System, Promega) 
and normalized against Renilla expression. 
 
RESULTS 
 
Decma treatment disrupts E-cadherin-
dependent cell-cell adhesion and induces uPA 
gene expression - Under normal growth 
conditions, T47D and MCF7 breast cancer 
epithelial cell lines grow very compact and E-
cadherin was concentrated at the border of the 
cell-cell interaction, corresponding to typical 
adhesive junction localization (Fig. 1A, a and c). 
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As described previously (25), Decma treatment 
destroyed tight cell-cell interaction, resulting in 
disruption of the epithelial layer (Fig 1A, b and 
d) and acquisition of a scattered phenotype (Fig. 
1B). In addition, E-cadherin disappeared from 
the plasma membrane and was redistributed into 
the cytoplasm, suggesting its internalization (Fig. 
1A, b and d). The loss of functional cell-cell 
adhesion became more apparent when MCF7 
cells were grown in Matrigel. Decma treatment 
led to the resolution of compact cell clusters and 
dissociation of the cells (Fig. 1C). To determine 
whether the disruption of cell-cell adhesion by 
Decma influenced expression of the uPA gene , 
we examined change in uPA mRNA levels. 
Northern blot analysis showed only barely 
detectable levels of uPA mRNA under normal 
growth conditions. However, an increase in uPA 
mRNA levels was observed already at 2 h after 
Decma treatment (Fig. 1D), whereas the control 
treatment (HA supernatant) had no effect. As a 
positive control, cells were treated with TPA, a 
potent inducer of uPA gene expression (16). 
 
Fig 1. Effects of Decma treatment on E-cadherin distribution, cell scattering and uPA expression. A, T47D 
cells (a and b) and MCF7 cells (c and d) were treated for 4 h with control or Decma supernatant and 
immunostained with anti-E-cadherin antibody recognizing the cytoplasmic part of E-cadherin. B, T47D cells (a 
and b) and MCF7 cells (c and d) were grown for 2 days to 60-70% confluence and then treated with control or 
Decma supernatant for 6 h before recording. C, MCF7 cells were grown overnight in Matrigel in the presence of 
control or Decma supernatant and stained with crystal violet to visualize cells before recording. D, MCF7 cells 
were treated with Decma and HA supernatant or 100 ng/ml TPA as indicated and subjected to Northern blot 
hybridization analysis for uPA and GAPDH mRNA levels. The uPA mRNA levels were normalized against 
GAPDH mRNA. 
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Fig 2. Role of Erk in Decma-induced uPA upregulation. A,B, T47D cells were treated for 30 min with 
different amounts of supernatant (A) or for different time periods (B) and total cell lysate was subjected to 
Western blot analysis for phospho-Erk levels. C, Comparison of phospho-Erk levels induced by different 
supernatants. MCF7 cells were treated for 30 min with Decma supernatant (Decma), Decma supernatant after 
Decma-depletion (Decma-depl.), anti-HA antibody-containing supernatant (HA) or control supernatant before 
analyzing the total cell lysates by Western blotting. For Decma-depleted supernatant, Decma supernatant was 
incubated with Protein A beads rotating overnight to pull down the antibody. D, MCF7 cells stably transfected 
with a pSuper retro-vector to express siRNA targeting E-cadherin or mouse-specific NCAM were treated for 30 
min with Decma, or 10 min with 50 ng/ml EGF, and total cell lysates were subjected to Western blot analysis for 
phospho-Erk status. E, MCF cells were co-transfected with a luciferase construct under the control of the uPA 
promoter and the Renilla plasmid overnight. Cells were then pretreated for 45 min with 10 µM UO126 (UO) as 
indicated and subsequently for 5 h with Decma or control supernatant before harvesting. Luciferase activity was 
measured and normalized against Renilla. 
 
Decma-induced uPA gene expression is 
dependent on Erk activation - We and others 
have shown that activation of Erk plays an 
important role in uPA gene expression (16,29). 
To determine whether Decma treatment caused 
activation of Erk, we investigated the 
phosphorylation status of Erk. Western blot 
analysis revealed a dose-dependent increase in 
Erk phosphorylation upon Decma treatment (Fig. 
2A). This phosphorylation peaked 10-15 min 
after Decma treatment and declined slowly, but 
remained at substantial levels for more than 3 h 
(Fig. 2B). Low and transient increase in Erk 
phosphorylation observed in control and HA-
treated cells (Fig. 2C) may be a response to 
medium change, which is known to activate Erk. 
To test whether the observed Erk 
phosphorylation was due to the blocking activity 
of Decma, we depleted Decma antibody 
molecules with Protein A-Sepharose. Treatment 
of MCF7 cells with this Decma-depleted 
conditioned medium had no pronounced effect 
on scattering (data not shown) or marked Erk 
phosphorylation (Fig. 2C). To test whether the 
observed Erk activation is a result of an 
interaction between Decma and E-cadherin, we 
examined the effect of the Decma-conditioned 
medium on cells expressing low amounts of E-
cadherin using an MCF7 cell line stably 
transfected with a pSuper retro vector expressing 
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an E-cadherin-specific siRNA. As a control, cells 
were stably transfected with a pSuper vector 
expressing siRNA to target mouse-specific 
NCAM, an mRNA that is not expressed in this 
cell line. Although, the knockdown of E-
cadherin was not complete, Decma-induced Erk 
activation was markedly lower under these 
conditions than in non-transfected or control 
cells (Fig. 2D). Thus the effect of Decma on Erk 
activation depends on the presence of the E-
cadherin protein. EGF-induced Erk activation 
was not affected in any of these cell lines. To 
acertain that Erk activation was a result of 
disruption of cell-cell adhesion and not merely of 
binding of an antibody to E-cadherin or to any 
given surface molecule, we treated MCF7 cells 
with a second anti-E-cadherin (E-cad2) and an 
anti-EGFR antibody. Both antibodies recognize 
the extracellular part of their respective proteins. 
In contrast to Decma, however, none of them 
induced disruption of cell-cell adhesion and 
scattering (data not shown). Western blot 
analysis revealed that in contrast to Decma 
treatment, neither treatment with the E-cad2 
antibody nor the EGFR antibody induced Erk 
activation (SupFig). Taken together, these results 
suggest that the observed Erk activation was 
specific for the disruption of cell-cell adhesion 
induced by blocking of E-cadherin via Decma. 
To find out whether Decma-induced Erk 
activation is necessary for enhanced uPA gene 
expression, we examined the effect on uPA 
promoter activity of the inhibitor UO126, which 
blocks MEK1, the upstream kinase of Erk. 
Transient transfection assays showed that Decma 
treatment strongly enhances uPA promoter 
activity, which was efficiently suppressed by 
pretreatment of the cells with UO126 (Fig. 2E). 
These results indicate that Decma treatment 
activates the uPA promoter through a signaling 
pathway involving Erk.  
Shc is necessary for Decma-induced Erk 
activation - Activation of Erk by various 
extracellular signals is often preceded by Shc 
phosphorylation. Accordingly, we examined Shc 
activation, as indicated by its tyrosine 
phosphorylation, and its association with Grb2. 
Both Shc activation and its Grb2 association 
increased after Decma treatment in MCF7 cells 
(Fig. 3A) and T47D cells (data not shown). 
RNAi experiments were performed to examine 
whether Shc activation is causally linked to Erk 
activation. Knockdown of all Shc isoforms by 
siRNA strongly decreased Erk phosphorylation 
in both MCF7 and T47D cell lines, while control 
siRNA had no effect (Fig. 3B). The observed 
impact on Erk activity was not a general effect of 
siRNA on Erk signaling since TPA-induced Erk 
activation was not affected by the same siRNA 
(Fig. 3B, right panel). To further test whether the 
inhibition of Erk activation was caused by the 
reduction in Shc protein, rescue experiments 
were performed using the siRNA-mediated 
knockdown-in approach (26). MCF7 cells were 
stably transfected with plasmids encoding single 
Shc isoforms, which carry silent mutations at the 
targeting site of the siRNA. These cell lines were 
further used for siRNA transfection to 
knockdown the endogenous proteins without 
affecting the silent mutant isoform. Fig. 3C 
shows that knockdown of Shc in control cells, 
transfected with the empty vector, markedly 
reduced Decma-induced Erk phosphorylation. 
This effect could be rescued by the expression of 
silent mutant p46Shc or p52Shc but not by silent 
mutant p66Shc. To mediate Erk activation, Shc 
proteins must be tyrosine phosphorylated on 
either Tyr239/240 or Tyr313 (Tyr317 in 
humans). Accordingly, expression of p52Shc3Y3F 
with all the three tyrosines mutated to 
phenylalanine did not rescue Decma-induced Erk 
activation (Fig. 3C). Moreover, Decma-induced 
Erk activation was already reduced by 
overexpressing p52Shc3Y3F and p66Shc without the 
knockdown of endogenous Shc, suggesting that 
they act in a dominant-negative manner. These 
results indicate that Decma-induced Erk 
activation is largely dependent on the p46shc and 
p52shc proteins. 
Involvement of Src  and PI3K in Decma-
induced Erk activation - The E-cadherin 
adhesion complex is linked to the actin 
cytoskeleton via catenin proteins. We showed 
previously that changes in the actin cytoskeleton 
induce Shc-dependent Erk phosphorylation and 
uPA upregulation in LLC-PK1 cells (28). 
Therefore, we examined whether Decma-induced 
Erk activation requires an intact cytoskeleton. 
Cytochalasin D (CytD) is a pharmacological 
agent that caps actin filaments and stimulates 
ATP hydrolysis on G actin, leading to a very 
rapid dissolution of the actin cytoskeleton (30). 
Pretreatment with CytD as well as simultaneous 
treatment with Decma and CytD at 
concentrations known to disrupt the cytoskeleton 
did not prevent Decma-induced Erk 
phosphorylation in MCF7 cells. CytD treatment 
alone had no effect on Erk phosphorylation in 
MCF7 cells but reduced the level in T47D cells. 
Nevertheless, treatment with Decma resulted in 
enhanced Erk phosphorylation irrespective of  
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Fig 3. Role of Shc in Decma-induced Erk activation. A, Effect of Decma on Shc phosphorylation and its 
association with Grb2. After treatment of cells with Decma supernatant for 30 min, 300 µg of total cell lysates 
were immunoprecipitated with anti-Shc antibody and subjected to Western blot analysis. B, Effects of Shc 
downregulation on Erk activation. Cells were transfected with control (C) or Shc (S) siRNA as described in 
“Materials and Methods” and treated 3 days later with Decma supernatant or 100 ng/ml TPA as indicated, 
followed by Western blotting for Shc, phospho-Erk and total Erk levels. C, Rescue by ectopic Shc isoform 
expression of Erk activation that was suppressed by downregulation of endogenous Shc. Stable cell lines 
expressing empty vector or silent mutants of HA-p46shc, HA-p52shc, HA-p52shc3Y3F, and HA-p66shc were prepared 
and transfected with siRNA targeting all Shc isoforms (S) or control siRNA (C). After 3 days transfection, cells 
were treated with Decma supernatant and total cell lysates were analyzed by Western blotting. 
 
CytD treatment (Fig. 4A). These results suggest 
that the actin cytoskeleton is not required for 
Decma-induced Erk activation. 
Some reports show a functional cross talk 
between E-cadherin and the EGFR (14,22,31). 
To determine whether Decma-induced Erk 
activation is a result of cross talk between E-
cadherin and the EGFR, which might then 
activate the Shc/Erk pathway, we examined 
whether EGFR activity was required for Erk 
activation. As shown in Fig. 4B, Decma-induced 
Erk phosphorylation was not affected by the 
EGFR-specific inhibitor PKI166, while EGF-
induced Erk activation was completely 
suppressed, indicating that Decma-induced Erk 
activation does not rely on transactivation of the 
EGFR. 
In a search for molecules other than Shc lying 
between E-cadherin and Erk in Decma-induced 
signaling, we made use of specific inhibitors of 
various kinases potentially involved in this 
signaling. Fig. 4C shows that Decma-induced 
Erk phosphorylation was completely suppressed 
by the Src-specific inhibitor CGP77675 as well 
as by the MEK1 inhibitor UO126 and partially 
attenuated by the PI3K inhibitor Wortmannin. 
No effect was observed with inhibitors of p38 
MAPK, Rho kinase or JNK, although their 
activities were confirmed by different control 
experiments (data not shown). These results 
show that not only MEK1 and Shc but also Src 
and PI3K are upstream of Erk in Decma-induced 
signaling. 
Role of Src in Decma-induced Erk 
activation - Since Src kinase activity was found 
to be necessary for Decma-induced Erk 
phosphorylation, we examined the activation of 
Src. Western blot analysis showed that Decma 
treatment enhanced Src phosphorylation of 
Tyr416, an indicator of Src activation (Fig. 5A). 
To assess whether Src is upstream of Shc, 
Decma-induced Shc tyrosine phosphorylation in 
the presence of the Src inhibitor CGP77675 was 
examined. Decma-induced Shc tyrosine 
phosphorylation and its association with Grb2 
were suppressed by the inhibitor, suggesting that 
Src is located upstream of Shc in this signaling 
cascade (Fig. 5B). Again, the Rho kinase 
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Fig 4. Effect of CytD and several kinase inhibitors 
on Decma-induced Erk activation. A, MCF7 and 
T47D cells were treated separately with Decma 
supernatant (Decma) for 30 min, with 3 µM CytD for 
30 min, with 3 µM CytD for 45 min followed by 
Decma for 30 min, or simultaneously with Decma and 
CytD for 30 min (boxed), and total cell lysates were 
analyzed by Western blotting for total and 
phosphorylated Erk levels. B, C, MCF7 cells were 
pretreated for 45 min with 5 µM PKI166 (B), 10 µM 
UO126 (UO), 5 µM CGP077675 (CGP), 1 µM 
SB263580 (SB), 100 nM Wortmannin (W), 10 µM 
Y27632 (Y27) or 20 µM SP600125 (SP) (C) and then 
treated with EGF for 10 min (B) or Decma for 30 min 
(C). Total cell lysates were analyzed as above.  
 
inhibitor Y27634 affected neither Decma-
induced Erk activation nor Shc phosphorylation 
and its association with Grb2 (Fig. 5B). 
Interestingly, Src inhibition also suppressed the 
disruption of cell-cell adhesion, the scattered 
phenotype of the cells and the redistribution of 
E-cadherin into the cytoplasm (Fig. 5C). 
Role of PI3K in Decma-induced Erk 
activation - The partial suppression of the 
Decma-induced Erk phosphorylation by 
Wortmannin suggests the involvement of PI3K 
in this signaling (Fig. 4C). Both Wortmannin and 
LY29400, two structurally distinct PI3K 
inhibitors, partially attenuated Erk 
phosphorylation but completely blocked Decma-
induced PKB phosphorylation (Fig. 6A). 
Interestingly, the Src kinase inhibitor CGP77675  
also blocked PKB phosphorylation, suggesting 
that Src acts upstream of PI3K in Decma-
induced signaling. Neither Shc phosphorylation 
nor its association with Grb2 were affected by 
Wortmannin (Fig. 6B). Shc knockdown resulted 
in attenuation of basal PI3K signaling as 
measured by PKB phosphorylation, but Decma 
treatment still enhanced PKB phosphorylation 
(Fig. 6C). Erk phosphorylation was completely 
suppressed when Shc knockdown and 
Wortmannin treatment were combined (Fig. 6C). 
Taken together, these results imply the presence 
of two parallel pathways downstream of Src 
leading to Erk activation, one mediated by Shc 
with a major contribution to Erk activation and 
the other mediated by PI3K with a minor 
contribution to Erk activation. 
Decma-induced uPA expression is 
dependent on Src and PI3K in addition to Erk - 
We show here that Src activation is necessary for 
Erk activation and that PI3K contributes 
partially. Also, Erk activation is necessary for 
Decma-induced uPA gene expression (Fig. 2E). 
As expected, we found that pretreatment with 
UO126 but also with CGP77675 abolished 
Decma-induced uPA activation (Fig. 7). 
Wortmannin, which only partially inhibited Erk 
activation (Fig. 6A), also reduced uPA gene 
expression to some extent. These results indicate 
that blockage of E-cadherin function induces 
uPA gene expression through signaling pathways 
involving these kinases . 
 
DISCUSSION 
 
Using the function-blocking antibody Decma, we 
showed previously that blockage of E-cadherin-
mediated cell adhesion results in the 
upregulation of uPA activation in MCF7 and 
T47D breast cancer cell lines (25). In this present 
study, we investigated the underlying molecular 
mechanisms and showed that disruption of cell-
cell adhesion induces Erk signaling downstream 
of E-cadherin. This Erk activation was Src- and 
Shc-dependent and resulted in enhanced 
expression of the uPA gene and, to a lesser 
extent, of the MMP-9 gene (data not shown). 
Disruption of cell-cell adhesion by calcium 
chelation using EGTA has been reported to 
increase Erk activity (13). Conversely, it was 
shown that E-cadherin adhesion suppresses basal 
Erk activity and concomitantly MMP-9 
expression (32). It may seem contradictory that 
Erk is also activated upon re-establishment of 
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Fig 5. Involvement of Src in Decma-induced Erk activation. A, Activation of Src by Decma. T47D cells 
were pretreated with 5 µM CGP077675 for 45 min (CGP) as indicated and then treated with Decma supernatant. 
Total cell lysates (400 µg protein) were immunoprecipitated with a polyclonal anti-Src antibody and then 
subjected to Western blot analysis for Src and phospho-Src (Y416). To discriminate between Src and the heavy 
chain antibody, the antibody was incubated with only protein A beads and lysis buffer (C1) or the cell lysate was 
incubated only with protein A beads (C2). B, Effect of Src inhibitor on Shc and Erk phosphorylation. T47D cells 
were pretreated for 45 min with 5 µM CGP077675 (CGP) or 10 µM Y27632 (Y27) and then treated with Decma 
supernatant for 30 min. Total lysates (250 µg total protein) were immunoprecipitated with anti-Shc antibody and 
then subjected to Western blot analysis (upper panel). In parallel, the total cell lysates (CL) were examined for 
Erk and phospho-Erk levels by Western blotting (lower panel). C, T47D and MCF7 cells were grown for 2 days 
to ca. 60% confluence. The cells were then treated for 45 min with 5 µM CGP077675 (CGP) (c, f, i, l) and 
subsequently for 4 h with Decma supernatant (b-c, e-f, h-i, k-l) before recording (a-f) or before immunostaining 
with the anti-E-cadherin antibody (g-l). 
 
cell-cell adhesion. However, the duration of 
this activation is much shorter and the 
underlying molecular mechanisms of the two 
systems are different. While Erk activation by 
the establishment of new cell-cell adhesion is 
transient (5-60 min) and dependent on EGFR 
(14) (22), Erk activation by the blockage of E-
cadherin was sustained (>3 h) and EGFR 
independent but Src- and Shc-dependent. 
Interestingly, RNAi-mediated downregulation 
of E-cadherin reduced Decma-induced Erk 
activation (Fig. 2D) but did not elevate basal 
Erk phosphorylation. These results suggest that 
it is not the absence per se of E-cadherin-
dependent cell-cell interaction that induces the 
signaling pathway. 
Src has been implicated previously in the 
control of cell adhesion. Inhibition of Src 
catalytic activity by overexpression of 
dominant inhibitory c-Src or by specific 
inhibitors stabilizes E-cadherin-dependent cell-
cell adhesion (33). Conversely, elevated Src 
activity leads to disorganization of E-cadherin-
dependent cell-cell adhesion and cell scattering 
(34). Fujita et al. (35) showed that E-cadherin 
and β-catenin become ubiquitylated by Hakai 
upon Src activation, ultimately leading to 
endocytosis of the E-cadherin complex. 
Accordingly, in the course of Decma-induced 
disruption of cell-cell adhesion, Src activation 
cell scattering and the redistribution 
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Fig 6. Role of PI3K in Decma-induced Erk 
activation. A, MCF7 cells were pretreated for 45 
min with 100 nM Wortmannin (W), 5 µM 
LY294002 (LY), or 5 µM CGP077675 (CGP) and 
then treated with Decma supernatant as indicated. 
Total cell lysates were subjected to Western blot 
analysis for phospho-PKB (Ser473), phospho-Erk 
and total Erk levels. B, MCF7 cells were treated 
with 100 nM Wortmannin for 45 min and then with 
Decma supernatant as indicated. Total cell lysates 
(400 µg protein) were immunoprecipitated with 
anti-Shc antibody and then analyzed for phospho-
Shc, total Shc and Grb2 by Western blotting. C, 
MCF7 cells were transfected with Shc-specific or 
control siRNA as described in Materials and 
Methods. After 3 days, transfected cells were 
pretreated with 100 nM Wortmannin for 45 min and 
then with Decma supernatant as indicated for 30 
min. Levels of phospho-PKB (Ser473), Shc, 
phospho-Erk and Erk in total cell lysates were 
determined by Western blotting. 
 
was necessary for the initiation of the signaling 
of E-cadherin into the cytoplasm. However, the 
mechanism of Src activation by Decma 
treatment has not been elucidated. The actin  
 
Fig 7. Role of Src, PI3K and Erk in Decma-
induced uPA upregulation. MCF7 cells were 
grown to 60-70% confluency, treated for 45 min 
with 10 µM UO126 (UO), 5 µM CGP077675 
(CGP) or 100 nM Wortmannin (W), and then with 
Decma supernatant as indicated. Total RNA (10 µg) 
was subjected to Northern blot analysis (lower 
panel). The uPA mRNA levels were normalized 
against GAPDH and presented graphically (upper 
panel). 
 
cytoskeleton seems not to be necessary for Src 
activation since CytD failed to prevent Decma-
induced Erk activation (Fig. 4A). One possible 
mechanism of Src activation is through the 
interaction with p120-catenin. p120-catenin is 
a Src substrate and has been shown to interact 
with Src kinase family members (36). This 
interaction is thought to keep Src kinases in an 
inactive state. Disruption of E-cadherin-
dependent cell-cell adhesion might change the 
interaction between E-cadherin/p120/Src 
family members which could allow Src 
activation. Alternatively, Src activation could 
be a result of a functional crosstalk between E-
cadherin and integrins. Intercommunication 
between integrins and cadherins has been 
observed several times (37,38) and 
Chattopadhyay et al. (39) recently reported a 
complex containing α3β1-integrins and E-
cadherin besides other proteins. In a indirect 
way loss of cell-cell adhesion might generate 
forces on focal adhesions which could produce 
integrin-dependent signals. All these 
possibilities are currently under investigation. 
Preliminary experiments suggest a functional 
cross talk between E-cadherin and integrins, 
given that siRNA-induced knockdown of β1-
integrin reduced Decma-induced Erk 
phosphorylation (unpublished data).  
Using siRNA against all isoforms of Shc, we 
found this adaptor protein to be essential for 
Decma-induced Erk activation. Moreover, 
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expression of silent mutants of Shc isoforms 
showed that only p46Shc and p52Shc rescued the 
effect of the siRNA. Overexpression of p66Shc 
not only failed to rescue Erk activation, but in 
fact had a negative effect comparable to the 
effect of overexpressed dominant negative 
p52Shc3Y3F. These results support previous 
observations that p66Shc is a negative regulator 
of EGF-induced Erk activation and c-fos 
promoter activation (21). In agreement with 
this, we showed recently that p66Shc is unable 
to rescue cytoskeleton reorganization-induced 
Erk activation after siRNA mediated 
knockdown of all isoforms of endogenous Shc 
(28). 
Decma-induced Shc tyrosine phosphorylation 
and its binding to Grb2 were completely 
repressed by pretreatment with a Src inhibitor, 
suggesting that Src acts upstream of Shc in 
Decma-induced signaling. In accordance with 
this observation, in vitro kinase assays have 
demonstrated that Src is able to phosphorylate 
all three tyrosine residues of Shc proteins 
directly (40) and is responsible for Shc 
phosphorylation upon fibronectin (41) and 
PDGF stimulation (42). FAK has been 
reported to form a complex with Shc and Grb2 
upon CytD treatment in LLC-PK1 cells (28) 
and upon fibronectin stimulation in NIH3T3 
fibroblasts (41). However, it is unlikely that 
FAK plays a role in Decma-induced Erk 
activation. No interaction of Shc and FAK was 
detected upon Decma treatment and 
overexpression of dominant-negative FRNK 
failed to abrogate Erk activation (data not 
shown). 
While the Src/Shc/Erk pathway plays a major 
role in Decma-induced Erk activation, Decma 
also induced the Src/PI3K/Erk pathway. 
Treatment of MCF7 or T47D cells with 
Wortmannin partially reduced Erk activation 
without affecting Shc phosphorylation. RNAi-
mediated knockdown of Shc reduced the basal 
activity of the PI3K pathway as measured by 
PKB phosphorylation. Nevertheless, Decma 
treatment still enhanced PKB phosphorylation, 
indicating a Shc-independent pathway for 
Decma-induced PKB activation. Effects of 
Wortmannin on Erk have been reported in 
several cell systems: in T lymphocytes (43), 
Cos 7 cells (44), and a CHO-derived cell 
line(45). However, the site at which the PI3K 
signaling feeds into the Erk activating pathway 
varies in these systems: at the Ras, Raf or 
MEK activation level. In the Decma-induced 
pathway, the signal from PI3K could 
contribute to Erk activation by acting at any of 
these sites, except upstream of Shc.  
We disrupted cell-cell adhesion by physical 
means using the function-blocking antibody 
Decma in order to reproduce a process 
observed in some types of tumorigenesis. 
During the course of tumor progression, the 
ectodomain of E-cadherin can be detached by 
matrilysin and stomilysin-1, releasing an 80-
kDA soluble E-cadherin fragment (sE-
cad)(10). sE-cad has been found in urine and 
serum of cancer patients and correlates with a 
poor prognosis (46-48). In tissue culture, it 
induces scattering of epithelial cells (49), 
inhibition of E-cadherin-dependent cell 
aggregation and invasion of cells into type I 
collagen (10). Furthermore, sE-cad stimulates 
the upregulation of MMP-2, MMP-9 and MTI-
MMP expression in human lung tumor cells, as 
reported by Noe and colleagues (10). To 
explain all these effects, the authors suggested 
the presence of a signal transduction pathway 
induced either directly by sE-cad or indirectly 
by the disruption of cell-cell contact (50). It 
may be argued that the signaling described in 
this report is a consequence of Decma acting as 
a ligand for E-cadherin. However, several lines 
of evidence suggest it is the disruption of cell-
cell adhesion that is attributable for Decma-
induced signaling activation. First, a second 
antibody against the extracellular domain of E-
cadherin which did not disrupt cell-cell 
adhesion did not induce Erk activation. 
Second, inhibition of Src blocked the 
disruption of cell-cell adhesion and at the same 
time prevented Erk activation. Third, Decma 
recognizes an eptiope located close to the 
membrane proximal part of the extracellular 
domain of E-cadherin (51). Structural changes 
in this membrane proximal region has been 
shown to change the adhesive properties of 
cells. Finally, Decma and sE-cad share 
common features that they disrupt cell-cell 
adhesion and induce signaling despite the fact 
that they interact with E-cadherin in different 
manners. Therefore, it is most likely that it is 
the disruption of E-cadherin-mediated cell-cell 
adhesion that triggers a signal transduction 
pathway leading to Erk activation and uPA 
gene expression. 
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Supplementary Fig. MCF7 cells were treated with 50 µg/ml of the indicated antibody for the indicated time. 
Total cell lysates were subjected to Western blot analysis for phospho-Erk and total Erk levels. 
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2.5 Supplementary data to 2.4 
 
2.5.1 Role of FAK in Decma-induced 
Erk activation 
 
We have shown that Src activity is 
necessary for Decma-induced Erk activation. 
The Focal Adhesion Kinase (FAK) is not only 
one of the major interacting partners of Src, 
but it can also activate Erk signaling through its 
interaction with Shc and Grb2 (Schlaepfer et 
al., 1999). We, therefore, asked whether FAK 
is activated upon Decma treatment, and found 
that its tyrosine phosphorylation is enhanced 
compared with the basal level (Fig. 2.5.1A). To 
further investigate whether FAK participates in 
Decma-induced Erk activation, the effect of 
overexpressed FRNK, a dominant-negative 
FAK mutant (Richardson and Parsons, 1996), 
was examined. FRNK expression had no effect 
on Erk phosphorylation, making  
 
Figure 2.5.1: Role of FAK in Decma-induced 
Erk activation. T47D cells were transiently 
transfected with pcDNA, HA-FAK, or HA-FRNK 
and then treated with Decma supernatant. 
Total cell lysates were immunoprecipitated 
with HA antibody (A) or directly subjected to 
Western blot analysis (B).  
a role for FAK in coupling Src activation to the 
Erk signaling pathway in this system unlikely 
(Fig. 2.5.1B). The functionality of the construct 
has been shown in another study from our 
laboratory (Irigoyen and Nagamine, 1999). 
 
2.5.2 Disruption of cell-cell adhesion 
using EGTA in LLC-PK1 cells 
 
In the non-transformed pig epithelial cell line 
LLC-PK1, the E-cadherin function-blocking 
antibody Decma does not disrupt cell-cell 
adhesion. However, E-cadherin-dependent 
cell-cell adhesion is calcium-dependent and 
can therefore be disrupted using calcium-
chelating agents such as EGTA. As illustrated 
in Fig. 2.5.2A, almost all E-cadherin protein 
that is normally localized at sites of cell-cell 
adhesion was internalized into the cytoplasm 
30 min after EGTA treatment. Similar to 
Decma treatment in MCF7 and T47D cells, 
EGTA treatment caused Erk activation, Shc 
phosphorylation, and Shc association with 
Grb2 (Fig. 2.5.2B, C). Knockdown of Shc using 
siRNA prevented EGTA-induced Erk 
phosphorylation, suggesting that Erk activation 
is dependent on Shc. Moreover, expression of 
HA-p46Shcsm and HA-p52Shcsm, which excaped 
targeting of the siRNA (knockdown-in), 
rescued sustained Erk phosphorylation 
induced by EGTA (Fig. 2.5.2D). In conclusion, 
EGTA disrupts cell-cell adhesion and induces 
Shc-dependent sustained Erk activation in a 
manner, which is reminiscent of the signaling 
induced by disruption of cell-cell adhesion 
using Decma in MCF7 and T47D cells. 
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Figure 2.5.2: A. Effect of EGTA on LLC-PK1 cells. LLC-PK1 cells were treated for 30 min with 4 mM 
EGTA and 1 mM MgCl2, and then immunostained with anti-E-cadherin antibody. B. LLC-PK1 cells 
were treated with 4 mM EGTA/1 mM MgCl2 or 50 ng/ml EGF for the indicated time, and total cell 
lysate was subjected to Western blot analysis. C. After treatment of cells with 4 mM EGTA/1 mM 
MgCl2 for 15 min, 300 µg of total cell lysates were immunoprecipitated with anti-Shc antibody and 
subjected to Western blot analysis. D. Cell lines stably expressing empty vector or HA-p46/52Shcsm 
were transfected with control or all-shc siRNA. Three days later, cells were treated with 4 mM EGTA/1 
mM MgCl2 for the indicated time and total cell lysate was analyzed by Western blotting.
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2.6 Role of p66Shc in regulating 
cell survival in epithelial cells 
 
p66Shc is implicated in the regulation of cell 
survival in response to oxidative stress, and 
the absence of p66Shc renders cells more 
resistant to UV-, H2O2-, or starvation-induced 
cell death (1.1.2.7) (Migliaccio et al., 1999; 
Nemoto and Finkel, 2002). This function of 
p66Shc has been attributed to the 
phosphorylation of the serine residue S36. 
Still, the precise mechanism underlying this 
role is not fully understood. In addition, it is not 
clear whether this is only restricted to certain 
cell types, such as fibroblasts, endothelial 
cells, and T-cells, or whether this represents a 
general mechanism. To investigate the role of 
p66Shc in regulating the survival of epithelial 
cells, p66Shc-expressing and non-expressing 
MCF7 cells (Fig. 2.3-2) were analyzed. 
Starvation, UV and H2O2 treatment of MCF7 
cells resulted in loss of cell viability as 
measured by trypan blue exclusion. However, 
no p66Shc-dependent change in cell viability 
was observed after any of these treatments 
(Fig 2.6-1). The same experiments were 
repeated with LLC-PK1 epithelial cells. 
Similarly to MCF7 cells, wild-type LLC-PK1 
cells do not express p66Shc. Again, p66Shc-
overexpressing cell lines were generated. 
Because the effect of p66Shc on stress-induced 
cell death was reported to be dependent on 
serine 36, cells overexpressing p66Shc carrying 
a serine to alanine mutation (S36A) at this site 
were made. Since p66Shc contains an 
additional threonine phosphorylation site with 
as yet unknown function, a mutation was 
introduced at this site too (T29A). Finally, cell 
lines overexpressing p66Shc containing serine
  
 
 
Figure 2.6-1: Effect of p66Shc overexpression 
on stress-induced cell death in MCF7 cells. 
Stable MCF7 cells expressing empty vector, HA-
p46Shc, HA-p52Shc, or HA-p66Shc were treated 
with 100 J/m2 UV or 1 mM H2O2, or were starved 
for 4 days. Cell viability was measured by trypan 
blue exclusion using the Vi-CELL analyzer at the 
indicated time point. 
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36/threonine 29 double mutation (TSA) were 
generated and, as control, cell clones 
expressing p66Shc mutated at serine 138 
(S138A), which is implicated in PTP-PEST 
binding (Fig 2.6-2). 
 
Figure 2.6-2: LLC-PK1 cells stably 
overexpressing p66Shc. LLC-PK1 cells were 
stably transfected to overexpress wild-type HA-
p66Shc and HA-p66Shc threonine or serine to 
alanine mutants. The depicted clones were 
used for further experiments.  
 
LLC-PK1 cells were more resistant to all 
stress-inducing agents, and higher doses were 
necessary to induce cell death. Again, 
overexpression of p66Shc did not render these 
cells more sensitive to UV- or H2O2-induced 
cell death (Fig 2.6-3A). In addition, no changes 
in cell viability were observed when either of 
the p66Shc phosphorylation mutants was 
overexpressed in these cells (Fig 2.6-3B). 
Various different experimental conditions 
(dosage of stress, duration after stress, 
starvation) were used, but we were unable to 
see p66Shc-dependent effects on cell viability in 
neither MCF7 nor LLC-PK1 cells, suggesting 
that p66Shc might not be involved in regulating 
cell survival upon stress in epithelial cells.
 
 
Figure 2.6-3: Effect of p66Shc overexpression on stress-induced cell death in LLC-PK1 cells. A. 
Two clones of stable LLC-PK1 cells expressing empty vector or HA-p66Shc were treated with 200 J/m2 
UV or 1 mM H2O2. B. Stable LLC-PK1 cells expressing empty vector, HA-p66Shc wild-type, HA-
p66ShcTSA, HA-p66ShcT29A, HA-p66ShcS36A, or HA-p66ShcS138A were treated with 200 J/m2 UV or 1.5 mM 
H2O2. Cell viability was measured by trypan blue exclusion using the Vi-CELL analyzer at the indicated 
timepoints. 
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3. Discussion 
 
3.1 Isoform-specific knockdown and 
knockdown-in of Shc using siRNA 
 
We have generated a system which allows 
downregulation and expression of single Shc 
isoforms in a short time period in tissue 
culture. This system should be applicable and 
functional for the study of almost all genes 
which are expressed as multiple isoforms. 
Moreover, the knockdown-in system can be 
useful for validating specificity or mutational 
analysis in follow-up experiments in which the 
target gene is restored by vector-based 
expression of a wild-type or mutated form of 
the gene. In our studies, coding sequences 
were targeted by siRNA. Therefore, the 
expression of siRNA-resistant proteins 
required point mutations in the region 
corresponding to the siRNA. Alternatively, 3’ or 
5’ UTR regions could be targeted 
(http://www.ambion.com/techlib/posters/RNAi_
0302.html) (Elbashir et al., 2002; Tsuda et al., 
2005). Targeting UTR sequences facilitates 
knockdown-in experiments because under 
these conditions it is unnecessary to introduce 
silent mutations in the vector-encoded genes. 
However, since UTR sequences are known 
sites of mRNA-binding proteins, some 
researches prefer to avoid these regions 
(Dykxhoorn et al., 2003; Elbashir et al., 2002). 
Although siRNAs are thought to act in a very 
specific manner, we observed side effects 
when siRNAs were used at high 
concentrations (100 nM). Nonspecific events 
were also noticed by other laboratories when 
siRNA concentrations of 100 nM or higher 
were used in mammalian cells. A comparison 
of expression profiles resulting from silencing 
of the same target gene by different siRNAs 
revealed siRNA-specific, rather than target-
specific, signatures including silencing of non-
targeted genes (Jackson et al., 2003). Another 
study has shown that transfection of siRNA at 
concentrations of 100 nM induced a significant 
number of genes, many of which are known to 
be involved in apoptosis and stress response 
(Semizarov et al., 2003). Reduction of the 
siRNA concentration to 20 nM eliminated this 
nonspecific response. Taking our observation 
and these reports into account, a number of 
different controls for siRNA experiments are 
recommended. In line with this, a recent 
editorial in Nature Cell Biology (2003) 
published a list of control experiments required 
for siRNA experiments. These include: (i) 
minimization of siRNA concentration, (ii) use of 
scrambled siRNA control, (iii) use of multiple 
siRNAs for a single target, (iv) examination of 
downregulation of mRNA and protein levels, 
and (v) rescue experiments as ultimate and 
best control. If a careful design of siRNAs, 
simlar to those published by Elbashir et al. 
(Elbashir et al., 2002) and Semizarov et al. 
(Semizarov et al., 2003), is combined with the 
suggested controls, siRNAs are a highly 
specific tool for targeted gene knockdown. 
In contrast to fungi, plants, and worms, 
which can replicate siRNA, there is no 
indication of siRNA amplification in mammals 
(Dykxhoorn et al., 2003). Likewise, we and 
others have shown the transient nature of 
siRNA-directed silencing by transfection into 
mammalian cells (Dykxhoorn et al., 2003). To 
prolong siRNA-induced knockdown, we 
suggested repeated transfection of siRNAs 
into cells. Later, several reports appeared 
which described vector-based siRNA 
expression systems (Amarzguioui et al., 2005; 
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Brummelkamp et al., 2002; Miyagishi and 
Taira, 2002; Yu et al., 2002). These allow 
stable expression of siRNA and can be 
designed in an inducible manner. Today, 
several strategies have been developed for 
RNAi in mammalian cells: they are 
summarized in Fig 3.1 (Kim, 2005).  
The study describing the isoform-specific 
knockdown and the knockdown-in was 
published at the beginning of 2002, when the 
mechanisms underlying siRNA-directed 
silencing were not fully understood. In this 
regard, our report not only offered a useful 
application of siRNA for the investigation of 
proteins expressed in multiple isoforms, but 
also gave some insights into the mechanisms 
of RNAi. These are discussed in section 2.1. 
Today, the mechanisms underlying RNAi have 
been well investigated (section 1.3). The use 
of RNAi has been further developed and it has 
become an effective, widely used method for 
the analysis of gene function. 
 
Figure 3.1: Various strategies for RNAi in mammalian cells. A. Long dsRNAs can induce specific 
RNAi in oocytes, early embryos, and undifferentiated embryonic stem cells. B. Chemically synthesized 
siRNA duplexes can be efficiently transfected into cultured cells. C. siRNA can be prepared in vitro 
from dsRNAs by incubating with recombinant Dicer protein. The diced products are purified based on 
their size (~21 nt) and transfected into cells. D. Short hairpin RNAs (shRNAs) are expressed in the 
nucleus from expression plasmids: the RNA polymerase (pol) III-derived expression system is shown 
here as an example. Upon export by Exportin 5 (Exp5), shRNAs are processed by Dicer-releasing 
siRNAs. E. ShRNA expression cassette can be delivered by viral vectors such as retroviral vector, 
lentiviral vector, and adenoviral vector (taken from (Dykxhoorn et al., 2003)). 
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3.2 Role of Shc in mediating 
Erk activation 
 
3.2.1 Shc is dispensable for EGF-
induced Erk activation 
 
Shc has been found as an adaptor protein 
that recruits the Grb2/SOS complex to the 
membrane in order to activate Ras, thereby 
coupling activated RTKs, such as EGFR, to 
Erk activation (Ravichandran, 2001). Through 
this action, Shc is involved in regulating the 
proliferation of mammalian cells (Pelicci et al., 
1992). In an attempt to study the isoform-
specific contribution of Shc proteins to EGF-
induced signaling, we applied the siRNA-
directed knockdown technique to several 
epithelial cell lines. Isoform-specific 
knockdown and knockdown of all Shc proteins 
did not influence EGF-induced Erk activation 
or response. Therefore, the results argue that 
EGF signaling is not dependent on Shc 
proteins in epithelial cells. Interestingly, Shc 
knockdown had also no effect on NGF-induced 
Erk activation in PC12 cells (data not shown). 
However, further experiments are required to 
investigate whether the absence of Shc has 
more subtle effects on EGF signaling. Shc acts 
upstream of Ras in EGFR signaling. We 
limited our investigation on Erk 
phosphorylation to the classical output of Ras 
activation. However, there are several lines of 
evidence suggesting that PI3K is another Ras-
effector molecule (Rommel and Hafen, 1998). 
Whereas stimulation of the Ras/Raf/Erk 
pathway is seen at very low concentrations of 
growth factors, PI3K activation is only 
observed at higher concentrations (Pawson 
and Saxton, 1999). Therefore, it can be argued 
that Shc knockdown reduces the extent of Ras 
activation which would still lead to the 
activation of the Raf/Erk pathway but would 
reduce Ras-mediated activation of PI3K. 
However, it is not clear whether this would 
have any physiological role, because PI3K is 
directly activated by EGFR. In a different 
cellular system, Hashimoto et al. (Hashimoto 
et al., 1999) have shown that Shc is not 
necessary for Ras activation by EGFR, but is 
important for JNK activation. It remains to be 
investigated whether JNK activation is 
changed upon Shc knockdown in epithelial 
cells. p66Shc has been proposed as a negative 
regulator of EGF-induced Erk activation. 
Isoform-specific knockdown of p66Shc did not 
change EGF-induced Erk activation in HeLa, 
PNT2, or PC3 epithelial cells. Conversely, no 
change in EGF-mediated cell viability or 
proliferation was observed when p66Shc was 
overexpressed. However, the experiments 
were done using 50 ng/ml EGF. Further 
experiments will show whether p66Shc 
influences these parameters at low EGF 
concentrations. 
Ignoring these cautions for a moment, the 
data represented here seem contradictory to 
the current established role of Shc proteins in 
cell signaling. However, reports which 
demonstrate that Shc is essential in mediating 
Erk activation downstream of EGFR are based 
on studies in which dominant negative Shc 
mutants were overexpressed (Gotoh et al., 
1995; Gotoh et al., 1997). It must be noted that 
the binding of Grb2 to EGFR, similar to most of 
the RTK, is redundant. Grb2 can be associated 
with the receptor either directly via its SH2 
domain or indirectly via binding to EGFR-
associated Shc and, most likely, Shp1 (Src 
homology phosphatase) (Chen et al., 1996; 
Hynes and Lane, 2005; Minoo et al., 2004) 
(Fig 3.2.1-1). Domain-mediated protein 
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interactions are dependent on both the affinity 
and the relative concentration of the binding 
partner: high affinity interaction would be 
favored at low concentrations of the target 
molecule, but could be displaced by low affinity 
interactions driven by high concentrations of 
affinity partners. Therefore, it is possible that 
overexpression of dominant negative Shc 
prevents the association of the receptor not 
only with endogenous Shc, but also with other 
proteins, such as Grb2, resulting in the 
inhibition of Erk activation. In contrast, the 
removal of Shc by siRNA would not interfere 
with the association of Grb2 or Shp1 with the 
receptor. Redundancy of adaptor proteins was 
also found in Drosophila. DShc, DRK (Grb2 in 
mammals) and DOS (daughter of sevenless) 
have been shown to act in parallel to 
transduce signals from the RTK torso 
(Luschnig et al., 2000). Therefore, loss-of-
function mutations in dshc affected RTK 
function only partially. Moreover, dShc seems 
to act in signaling of only a subset of RTKs, 
indicating that dShc confers specificity to 
receptor signaling. In mammals, Shc is 
phosphorylated downstream of all RTKs 
known to date (Luzi et al., 2000). However, the 
physiological relevance of Shc phosphorylation 
might depend on the repertoire of other 
adaptor proteins expressed at the same time. 
The relative contribution of Shc to signaling of 
each of the receptors should be addressed 
using siRNA-mediated knockdown, and not 
overexpression dominant negative Shc. The 
existence of interactions between Shc and 
Grb2 with EGFR, with each other, and with a 
subset of cellular proteins raises the question 
of how interactions are controlled. Do all 
possible interactions occur in a single cell and, 
if so, does activation of one pathway influence 
activation of alternative pathways?  
Figure 3.2.1-1: Schematic representation of 
the main autophosphorylation sites in 
EGFR and of signaling molecules 
associated with these sites. Each receptor 
chain becomes phosphorylated on multiple 
sites and binds specific SH2-containing 
proteins. The receptor has redundant 
interactions, for example with Grb2. This figure 
is illustrative and not comprehensive: some 
binding partners and pathways, including PI3K, 
Src, and STATS, are not depicted. 
 
As already mentioned above, protein 
interactions are influenced by their binding 
affinity to each other and by their relative 
concentrations. It is also important to 
recognize that the “local” abundance of a 
protein may determine its availability for 
binding: co-localization will favor interaction 
even when affinity is low. Protein association 
patterns can vary within the same cell 
depending on the stimulus and timing of the 
stimulation. Preliminary data suggest that Shc 
proteins might play a role in stress-induced 
activation of MAPKs. In LLC-PK1 cells, 
knockdown of Shc did not alter Erk activation 
induced by EGF and TPA (Fig 3.2.1-2 lanes 1-
6). However, Erk activation was slightly 
reduced after H2O2 and UV treatment in the 
absence of Shc (Fig 3.2.1-2 lanes 7-10). 
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Interestingly, only expression of p66Shc 
(knockdown-in) enhanced the reduction of 
H2O2- and UV-induced Erk activation seen 
before (Fig 3.2.1-2 lanes 17-20). Similar 
effects were seen for JNK activation (Fig 3.2.1-
2 lane 13-18). These results indicate that Erk 
and JNK activation stimulated by stress, such 
as UV and H2O2, are mediated, at least 
partially, by Shc proteins and that p66Shc is 
able to modulate this MAPK activation.  
Interactions between various proteins are 
also controlled in a tissue-dependent manner. 
Different cell types may favor different protein 
associations. Shc is most highly expressed in 
adipocytes, smooth muscle cells, and cardiac 
myocytes. The Shc knockout embryo died 
because of defects in heart development and 
the cardiovascular system. Therefore, Shc is 
expected to play a more important role in these 
tissues, and future experiments to deepen our 
understanding of the underlying molecular 
mechanisms of Shc should target these 
tissues.  
 
3.2.2 Shc mediates Erk activation 
downstream of E-cadherin  
 
Loss of Shc affects fibrocectin-induced Erk 
activity, focal complex distribution, the actin 
cytoskeleton, and cell-cell contacts (Lai and 
Pawson, 2000). In addition, Wary et al (Wary 
et al., 1996) demonstrated that Shc is 
necessary for integrin-induced Erk activation, 
and we have shown that Shc plays an 
essential role in CSR-induced Erk activation 
(Faisal et al., 2004). Taken together, these 
results suggest that Shc might be important for 
Erk activation mediated by non-receptor 
tyrosine kinases. We have recently shown that 
uPA secretion is induced upon disruption of 
 
 
 
Figure 3.2.1-2: Effect of Shc knockdown and p66Shc overexpression on MAPK activation. LLC-
PK1 cells expressing either empty vector or p66Shc were transfected with buffer (B) or si-shc1 (S) and 
three days later treated with 50 ng/ml EGF, 100 nM TPA, 1 mM H2O2, or 200 J/m2 UV. Total cell lysate 
was analyzed by Western blotting. Boxes indicate changes in the phosphorylation level of Erk or JNK 
in dependence on Shc proteins. 
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cell-cell adhesion (Frixen and Nagamine, 
1993). Knowing that uPA gene expression is 
often regulated through stimulation of the 
MAPK pathway (Besser et al., 1995a; Besser 
et al., 1995b; Irigoyen and Nagamine, 1999) 
the question was raised of whether disruption 
of cell-cell adhesion induces MAPK activation, 
and whether Shc would play a role in 
mediating this MAPK activation. 
In section 2.3 we describe and discuss the 
fact that disruption of E-cadherin-dependent 
cell-cell adhesion does indeed stimulate a 
previously unknown signaling pathway (Fig 
3.4.2). This pathway directly links disruption of 
E-cadherin-dependent cell-cell adhesion to the 
induction of the uPA gene, two events which 
are strongly involved in metastasis. Upon 
disruption of cell-cell adhesion through the 
function-blocking antibody Decma, Src 
becomes activated and induces Shc/Grb2 
association leading to the activation of Erk and 
finally to uPA gene expression. On the other 
hand, Src mediates PI3K and PKB activation. 
PI3K activation contributes partially to Erk 
activation.  
 
 
 
Figure 3.2.2: Schematic representation of the signaling pathway induced by disruption of E-
cadherin-dependent cell-cell adhesion. Perturbation of E-cadherin-dependent cell-cell adhesion 
leads to Src activation, followed by p46/p52Shc phosphorylation, which mediates Erk activation through 
Ras/Raf/MEK1. This results in enhanced uPA gene expression. Active Src also mediates PI3K/PKB 
activation. PI3K signaling contributes to Erk activation.  
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Proteolytic cleavage of E-cadherin by MMPs, 
such as ADAM10, has been shown to induce 
translocation of β-catenin into the nucleus and 
increase the expression of the β-catenin 
downstream gene cyclin D1 (Maretzky et al., 
2005). uPA has also been described as a 
target of β-catenin (Hiendlmeyer et al., 2004). 
Therefore, it would be interesting to see 
whether Decma-induced uPA gene expression 
is partially mediated by β-catenin. It is worth 
noting that the same amount of β-catenin co-
immunoprecipitated with E-cadherin at least 30 
min after Decma treatment (data not shown). 
Similarly, using immunostaining we could not 
detect nuclear β-catenin localization upon 
Decma treatment (data not shown). However, 
we did not perform a promoter activation assay 
to see whether TCF/LEF-dependent 
transcription becomes activated upon 
disruption of cell-cell adhesion through Decma.  
Disruption of cell-cell adhesion using EGTA 
also induced Shc-dependent Erk activation in 
LLC-PK1 cells (section 2.5.2 Fig. 2.5.2), 
indicating that the signaling pathway described 
earlier is not restricted to Decma-induced 
disruption of cell-cell adhesion. Interestingly, a 
recent report shows that disruption of cell-cell 
adhesion using EGTA leads to the activation of 
the small GTPase Rap1, a crucial regulator of 
inside-out activation of integrins (Balzac et al., 
2005). The authors also observed an increase 
in Src activity, which was required for Rap1 
activation. Further investigation revealed that 
E-cadherin endocytosis is necessary for Rap1 
activation. Src is a major player in regulating 
endocytosis of E-cadherin (Frame, 2002; Fujita 
et al., 2002; Palovuori et al., 2003). Treatment 
of the Src inhibitor prevented disruption of cell-
cell adhesion and internalization of E-cadherin 
upon treatment with Decma. Therefore, it 
would be interesting to see whether Decma-
induced Erk activation is dependent on E-
cadherin endocytosis. However, CytD 
treatment, which is believed to block E-
cadherin internalization through disruption of 
the actin cytoskeleton, did not inhibit Erk 
activity, arguing against this possibility (section 
2.3 Fig 4). To find a conclusive answer, 
experiments using specific pharmacological 
inhibitors of endocytosis have to be done.  
In this study, we clearly showed that Decma-
induced Erk activation can be mediated by 
p46/p52Shc but not by p66Shc. Moreover, 
overexpression of p66Shc led to a dominant 
negative pattern. The reason for p66Shc being 
unable to rescue Decma-induced Erk 
activation is not understood. In a different 
study, we have shown that p46/p52Shc, but not 
p66Shc, rescued CSR-induced Erk activation in 
LLC-PK1 cells (Faisal et al., 2004). 
Investigation of the p66Shc phosphorylation 
status revealed that p66Shc was not 
phosphorylated at its tyrosine residues upon 
CSR. On the other hand, overexpression of 
p66Shc had no dominant negative effect on 
CSR-induced Erk activation. We have not 
investigated yet whether p66Shc becomes 
tyrosine-phosphorylated upon disruption of 
cell-cell adhesion. The fact that its 
overexpression interfered with Decma-induced 
Erk activation argues for an active role of 
p66Shc in this signaling. A mechanism where 
p66Shc competes with the other isoforms for 
Grb2 binding, or where p66Shc binds to 
RasGAP to downregulate Ras activation as 
described in section 1.1.2.6 (Fig 1.1.2.6-1), can 
be envisioned. More experiments will be 
needed to test this hypothesis. However, the 
action of p66Shc seems to be cell type- and/or 
stimulus-dependent. 
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Taken together, we found that Shc is not 
essential for growth-factor-induced Erk 
activation. In contrast, we found a novel 
pathway downstream of E-cadherin in which 
p46/p52Shc are required to mediate Erk 
activation. In context with other studies 
showing that the absence of Shc impairs focal 
complex distribution, the actin cytoskeleton, 
and cell-cell contacts (Lai and Pawson, 2000), 
as well as that Shc is essential for CSR- and 
integrin-induced Erk activation (Faisal et al., 
2004; Wary et al., 1996), we propose that Shc 
proteins play a more important role in 
mediating growth factor-independent Erk 
activation which involves the action of soluble 
tyrosine kinases. This hypothesis is also 
supported by in vivo studies demonstrating that 
Shc is essential for signaling downstream of 
the pre-TCR that uses non-receptor tyrosine 
kinases to phosphorylate Shc proteins (Pacini 
et al., 1998; Zhang et al., 2002). 
 
3.3 The role of p66Shc in stress 
response 
 
The absence of p66Shc confers resistance to 
oxidative stress in mouse embryo fibroblasts, 
endothelial cells, and T-cells (section 1.1.2.7). 
We wanted to use two epithelial cell lines to 
study p66Shc function and the role of its serine 
and threonine phosphorylation sites in 
mediating the oxidative stress response. It was 
expected that sensibility to oxidative stress-
induced apoptosis would be enhanced upon 
introduction of p66Shc in non-p66Shc expressing 
cells, similar to what has been reported for 
p66Shc-deficient MEFs (Migliaccio et al., 1999). 
Surprisingly, p66Shc expression did not change 
the viability of these cells upon treatment with 
various stress-inducing agents. Although the 
experimental setup was changed, no 
conditions were found in which p66Shc 
expression decreased the viability of these cell 
lines upon stress induction. The functionality of 
the HA-p66shc constructs have been proven 
before in other studies (Faisal et al., 2002; 
Faisal et al., 2004).  
The simplest explanation for these 
contradictory results would be that we did not 
find the right experimental conditions, or that 
we chose the wrong cell lines. LLC-PK1 is a 
non-transformed proximal tubular epithelial cell 
line which has been used to study apoptosis in 
response to oxidative stress (Al-Ghamdi et al., 
2004; Allen et al., 2003; Rustom et al., 2003). 
However, LLC-PK1 cells turned out to be 
highly resistant to any stress-inducing agents. 
MCF7 cells are breast cancer cells. It is not 
clear whether the apoptotic response in 
transformed cells is regulated by p66Shc. 
However, both cell lines express p53, which 
becomes stabilized upon treatment with UV or 
H2O2 (data not shown).  
These results could also imply that, in 
epithelial cells, p66Shc is not involved in the 
regulation of cell viability in response to 
oxidative stress. To date there has been no 
report demonstrating a p66Shc-dependent 
regulation of apoptosis in epithelial cells. Other 
factors specific for epithelial cells could take 
over the role of p66Shc in this regard. One 
possible candidate is the newly identified 
protein REDD1 which is a downstream target 
of p63, a p53 family member (Ellisen et al., 
2002). REDD1 was identified as a hypoxia-
inducible gene involved in the regulation of 
cellular ROS (Shoshani et al., 2002). Similar to 
p66Shc, overexpression of REDD1 desensitizes 
cells to apoptotic stimuli, and loss of REDD1 
expression results in reduced intracellular ROS 
levels and enhanced resistance to oxidative 
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stress-induced apoptosis (Ellisen et al., 2002; 
Schwarzer et al., 2005). Remarkably, REDD1 
is involved in epithelial development and is 
specifically expressed in tissues derived from 
the ectoderm (Ellisen et al., 2002). Therefore, it 
is possible that REDD1 represents an 
epithelial-specific factor involved in the 
regulation of ROS and cell viability. However, 
to exclude a role for p66Shc in this process, 
more epithelial cell lines should be examined. 
 
3.4 Isoform-specific role of 
p46Shc 
 
Beside the isoform-specific role of p66Shc in 
regulating apoptosis, it remains unclear 
whether p46Shc and p52Shc display different 
functions. Both seem to be equally involved in 
mediating MAPK activation, as shown here 
and in other reports (Faisal et al., 2004; 
Ravichandran, 2001). On the other hand, there 
are some indications for variation in their 
function. p52Shc can be phosphorylated on 
serine 29 and it has been shown that this 
phosphorylation is necessary for its binding to 
the phosphatase PTB-PEST in order to 
downregulate insulin-induced Erk activation 
(Faisal et al., 2002). An investigation of the 
subcellular localization of Shc isoforms 
revealed a specific and selective localization of 
p46Shc to the mitochondrial matrix (Ventura et 
al., 2004). Deletion mapping experiments have 
demonstrated that targeting of p46Shc to 
mitochondria is mediated by its first 32 amino 
acids, which behave as a bona fide 
mitochondrial targeting sequence. Further, it 
has been shown that the N-terminal location of 
the signal peptide is critical for its function. This 
accounts for the observation that p52Shc and 
p66Shc, containing the same sequence but 
more internally located, display a remarkably 
different subcellular localization. These 
findings indicate that p46Shc may exert a non-
redundant biological function in signal 
transduction pathways involving mitochondria.  
Another group has reported that p46Shc is 
specifically and heavily phosphorylated in 
proliferating hepatocytes and cancer cells 
derived from liver, and localizes in both the 
nuclei and the cytoplasm of these cells 
(Yoshida et al., 2004; Yuji et al., 2004). The 
authors suggest that p46Shc localization in the 
nuclei may be closely related to 
hepatocarcinogenesis and represents a useful 
marker for the detection of hepatocytes with 
high proliferative activity. The same laboratory 
reported p46Shc nuclear localization in gastric 
normal mucosa and cancer, also suggesting a 
role for p46Shc in gastric carcinogenesis 
(Yukimasa et al., 2005). However, the question 
of what is the function of p46Shc in the nucleus 
remains unanswered.  
In contrast, Murayama et al. (Murayama et 
al., 2004) demonstrated that antibody ligation 
of CD9 induced apoptosis of gastrointestinal 
cancer cell lines in a p46Shc-dependent 
manner.  
Taken together, these results indicate that in 
some tissues p46Shc seems to play a more 
important role than p52Shc. Specific conditional 
knockout studies would help to further our 
understanding of the physiological role of Shc 
isoforms. 
 
3.5 Conclusion  
 
This thesis introduces a tool for the analysis 
of single Shc isoforms in tissue culture. Using 
this tool, we found that p46/p52Shc, but not 
p66Shc, play an essential role in a previously 
unknown signaling pathway downstream of E-
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cadherin. This pathway directly links disruption 
of E-cadherin-dependent cell-cell adhesion to 
expression of the uPA gene and might 
therefore play a role in tumor progression. Shc 
proteins play an important role in mediating 
MAPK activation. However, receptor tyrosine 
kinases have redundant ways of coupling to 
the MAPK pathway and the individual 
contribution of various adaptor proteins is not 
known. Data provided in this thesis suggest 
that p46/p52Shc are exchangeable for growth 
factor-induced MAPK activation but play a 
more important role in growth factor-
independent MAPK activation. 
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4. MATERIAL AND METHODS 
 
The following chapter adds additional 
material and methods used in chapter 2 which 
have not been described before. 
 
Cell lines. The renal proximal tubular cell 
line LLC-PK1 was cultured in Dulbecco's 
modified Eagle's medium (Invitrogen), 
supplemented with 10% (v/v) fetal calf serum 
(AMIMED, Allschwil, Switzerland), 0.2 mg/ml 
streptomycin, and 50 units/ml penicillin. For 
serum starvation, cells were incubated in 
Dulbecco's modified Eagle's medium 
containing 0.1% fetal calf serum. The human 
prostate epithelial cell line PNT2, and the 
human prostate adenomcarcinoma cell line 
PC3, were cultured in RPMI medium 
supplemented with 10% (v/v) fetal calf serum, 
0.2 mg/ml streptomycin, and 50 units/ml 
penicillin. All cells were grown at 37°C in a 
humidified incubator with 5% CO2. For serum 
starvation, cells were incubated in their 
medium containing 0.1% fetal calf serum. 
 
EGTA treatment. LLC-PK1 cells were 
starved for 16 h and then treated with 4 mM 
EGTA and 1 mM MgCl2 for an additional 30 
min if not indicated differently. 
 
MTT proliferation assay. HeLa, PNT2, 
PC3, and LLC-PK1 cells were transfected with 
siRNA. The next day, 100-500 cells/well 
(depending on the cell line) were seeded in 
triplicate in 96-well plates. The cells were 
grown in 100 µl medium for 3 days, at which 
time 10 µl of a 5 mg/ml stock solution MTT (3-
(4,-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium) (Boehringer Mannheim) was 
added to each well and incubated for an 
additional 4 h. The MTT is converted to a color 
crystal product by mitochondrial enzymes, 
which are then dissolved by adding 100 µl of a 
0.01 M HCl solution containing 10% SDS for 8 
h. Color development was measured 
spectrophotometrically on an ELISA reader at 
a wavelength of 590 nm. Proliferation of control 
cells was set 100%. 
 
p46/52Shc siRNA. The following 21-mer 
oligoribonucleotide pair was used as si-
p46/p52Shc: 5’-GUG CGG AGA CUC CAU 
GAG GCC-3’ and 5’-CCU CAU GGA GUC 
UCC GCA CGC-3’. The specificities of these 
sequences were confirmed by blasting against 
the GenBank/EMBL database. 
 
Viability assay. 1.5x106 cells were seeded 
in 6 cm plates. The next day, first samples 
were collected (day 0) and the others were 
starved or treated with EGF, H2O2, or UV 
according to the experiment. At the indicated 
timepoint, cells were trypsinized and diluted in 
1 ml of medium, and cell number as well as 
viability was measured in the Vi-CELL analyzer 
using the trypan blue exclusion. All samples 
were done in duplets. 
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Ang II  Angiotensin II 
APC  adenomatous poliposis coli 
CH  collagen homology domain 
CSR  cytoskeletal reorganization 
DCR  dicer-like protein 
DN  double negative stage 
DP  double positive stage 
dsRNA double-stranded RNA 
EGF  epithelial growth factor 
EGFR EGF receptor 
EMT  epithelia-to-mesenchymal  
  transition 
Erk  extracellular activated kinase 
FAK  focal adhesion kinase 
FKHRL Forkhead family transcription 
factor 
Gab  Grb2-associated binding protein 
GAP  GTPase activating protein  
GPCR G protein-coupled receptors 
Grb2 growth-factor-receptor binding 
protein-2 
GTP  guanonsine triphosphate 
HGF  hepatocyte growth factor 
ICAP-1 integrin cytoplasmic domain- 
  associated protein-1 
IL  interleukin 
IRS  insulin receptor substrate 
IGFR  insulin-like growth factor   
  receptor 
JNK  jun N-terminal kinase 
LEF  lymphocyte-enhancer factor 
MAPK mitogen activated protein  
  kinase 
MEFs  mouse embryonic fibroblasts 
Memo mediator of ErbB2-driven cell 
motility 
miRNA microRNA  
miRNP micro ribonucleoprotein particle 
MMP  matrix-metallo protease 
NGF  neuronal growth factor 
PBL  peripheral blood lymphocytes 
PDGF platelet-derived growth   
  factor  
PH  pleckstrin homology domain 
PI3K  phosphatitylinositol-3 kinase 
PI(4)P phosphoinositol 4-phosphate 
PI(4,5)P2 phosphoinositol 4,5-diphosphate 
PI(3,4,5)P3 phosphoinositol 3,4,,5-phosphate 
PKB  protein kinase B (Akt) 
PP2A  protein phosphatase type 2A 
PTB  phosphotyrosine binding domain 
R2D2   dsRNA binding protein 
RISC  RNA-induced silencing   
  complex 
RNAi  RNA interference 
ROS  reactive oxygen species 
Shc  Src-homology and collagen- 
  like protein 
Shp2  Src homology phosphatase- 
  1 
SHIP SH2-containing inositol 
polyphosphate 5-phosphatase 
SOS  son of sevenless 
SP  single positive stage 
siRNA small interfering RNA 
SH  src-homology domain 
TCR  T-cell receptor 
TCF  T-cell factor 
TGF-β transforming growth factor-β 
uPA  urokinase plasminogen activator 
UV  ultraviolet light 
TPA  12-O-tetradecanoylphorbol-13  
  acetate 
VEGF  vascular endothelial growth factor 
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